Salesforce stock has plunged by more than 50% from its December 2024 peak as concerns about its growth outlook have intensified. Its market capitalization has fallen from more than $347 billion to about $136 billion, and the selloff could continue as investors remain concerned about the company's strategy and long-term growth prospects.
CRM stock has been in a steep decline over the past few years as concerns about its growth have escalated. Recently, the stock has dropped because of the rising SaaSpocalypse fears.
SaaSpocalypse is a relatively new term referring to fears that AI agents will replace traditional software and the “per seat” pricing model. A good example of this is what Starbucks is doing.
According to Bloomberg, the company is now building its own AI-assisted replacement for a Microsoft system that tracks inventory and an IBM solution that manages maintenance. It aims to save the $400 million it spends annually on software.
The fears in the software industry escalated this week after IBM published its financial results. IBM said that its business slowed as customers reprioritized their capital expenditure, redirecting it towards hardware purchases like servers and memory.
Salesforce’s organic growth has been slowing for a while. The most recent results showed that its revenue rose by 13% in the first quarter. While this growth is solid for a company that has been in business for years, it was not organic. Its $11.1 billion revenue included $444 million from Informatica, a company it acquired in a $8 billion deal.
The company has been one of the most acquisitive ones in the US. It has spent billions of dollars acquiring firms like Own Company, Fin, Bluebirds, Tableau, and Slack.
Analysts expect that Salesforce’s business will remain under pressure in the coming months. The average estimate is that its revenue jumped by 10% in the last quarter to $11.32 billion. Its annual revenue is expected to be $46.1 billion, followed by $50.4 billion next year.
At face value, there are signs that Salesforce stock has become a bargain. For one, its Non-GAAP forward price-to-earnings ratio has dropped to 11.8, well below the sector median of 24. Its five-year average stands at 24.
Similarly, the forward PEG ratio stands at 0.73, also lower than other companies in the tech industry. The challenge, however, is that these valuation metrics include the extra funds made from its Informatica buyout.
As a result, the company will need more growth catalysts over time. One of this catalysts will be its Agentforce and data segments, whose annual recurring revenue soared to $3.4 billion, a 200% jump. It has deployed over 3.8 billion Agentic Work Units (AWU) across Agentforce and Slack.
READ MORE: Salesforce stock falls after KeyBanc downgrade on AI growth concerns
Salesforce stock chart | Source: TradingView
The weekly chart shows that the CRM share price has slumped in the past few years, moving from a record high of $367 to a low of $146. It remains below the 50-week Exponential Moving Average (EMA).
The stock has also remained below the Supertrend indicator and the 78.6% Fibonacci Retracement level.
Therefore, the stock will likely remain under pressure in the near term. In this, it may drop and retest the year-to-date low of $146.
In the long-term, however, the stock will likely bounce back as investors buy the dip in software stocks.
New software solutions integrate planning and scheduling processes to accelerate decision-making
Crude Schedule Optimization and Multi-Blend Optimization available in a single, integrated platform Improves refinery margins by automating time-intensive manual workflows Enables refineries to respond more quickly to market volatility and optimize product blending , /PRNewswire/ -- Global automation leader Emerson (NYSE: EMR) has introduced software that automates two of refining's most time-intensive and margin-critical processes: crude scheduling and product blending. The new solutions enable refineries to increase operating margins, improve efficiency and respond faster to market changes.
Customers use Aspen Unified Scheduling™ (AUS) to eliminate the disconnected tools and manual data gathering that make scheduling harder during volatile markets. AUS now adds two new products – Crude Schedule Optimization and Multi-Blend Optimization – that bring planning, scheduling and blending into one platform. As a result, customers can turn optimal plans into realistic schedules fast enough to keep up with changing market conditions.
"Refinery schedulers are managing more complexity and greater crude market volatility, with the same hours in the day," said Claudio Fayad, chief technology officer at Emerson's Aspen Technology business. "By automating the most time-intensive workflows within a unified platform, our solutions free experienced teams to focus on higher-value decisions while enabling newer engineers to contribute faster. The result is stronger margins and better operational decisions across the organization."
Optimizing Crude Scheduling
Crude Schedule Optimization takes refinery data from Aspen Unified PIMS™ and automatically determines the optimal crude receipts, transfers, blends and production schedules to maximize margins. By minimizing manual work and enabling rapid "what if" scenario testing, refineries can improve scheduling precision, thereby reducing errors and enabling rapid response to crude market fluctuations and price opportunities.
Maximizing Blending Efficiency
Multi-Blend Optimization simultaneously optimizes the recipe of each individual batch of blended product within the scheduling window. It continuously optimizes product qualities and balances production against market conditions and operational constraints, while ensuring compliance with quality specifications. By making optimal use of available blend components, refineries reduce quality giveaway, lower blend component costs and improve profitability.
Both solutions are offered as separately licensed products available within Aspen Unified Scheduling. As part of the broader Aspen Unified™ solution, Aspen Unified Scheduling connects data, optimization and execution – reducing manual intervention, improving operational consistency and accelerating the speed of critical business decisions.
Additional Resources:
Learn more about Aspen Unified Scheduling Join the Emerson Exchange 365 Community Visit Emerson's Industrial Software Page on LinkedIn Connect with Aspen Technology on LinkedIn Connect with Emerson via X Facebook LinkedIn YouTube About Emerson
Emerson (NYSE: EMR) is a global automation leader delivering solutions for the most demanding technology challenges. Headquartered in St. Louis, Missouri, Emerson is engineering the autonomous future, enabling customers to optimize operations and accelerate innovation. For more information, visit Emerson.com.
Alibaba Group (BABA) and Baidu (BIDU) shares advanced after both companies confirmed partnerships with Apple (AAPL) to support the rollout of Apple Intelligence
Image Credits:Apple (event screenshot) Apple Intelligence, the iPhone maker’s generative AI offering, is coming to China.
On Wednesday, Reuters reported that China’s internet content regulator, the Cyberspace Administration of China, approved Apple’s AI services in the country on the back of a deal to integrate Alibaba’s Qwen AI model into Apple’s operating systems, including iOS, iPadOS, macOS, and visionOS.
On Wednesday evening, a Baidu spokesperson confirmed to TechCrunch that it is also working with Apple on developing Apple Intelligence features for Chinese users.
The Alibaba deal, which was rumored to be in the works last year, marks an important step for Apple’s AI ambitions in a key market. In the second quarter, Apple generated $20.5 billion in sales in Greater China, up 28% from a year earlier. Apple also recently regained its No. 2 position in China’s smartphone market after a recent shopping festival offered discounts on the iPhone lineup.
The Baidu partnership was also rumored, but reports at the time claimed Apple was facing issues adapting its models for Chinese customers. Apple is also said to be exploring integrations with DeepSeek and ByteDance.
A lack of approval by Chinese regulators has led to Apple Intelligence features, which debuted in 2024, being delayed in the Chinese market.
Alibaba earlier confirmed the company’s news to CNBC in a statement, saying that its Qwen models would be “integrated into Apple Intelligence experiences,” though it did not provide a time frame. It also said the integrations would involve AI capabilities like “text and image understanding and generation.”
This article was updated Thursday, July 16, to add the statement by Baidu.
Commerce Bancshares (CBSH - Free Report) came out with quarterly earnings of $1.1 per share, beating the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +5.77%. A quarter ago, it was expected that this bank holding company would post earnings of $0.94 per share when it actually produced earnings of $0.96, delivering a surprise of +2.13%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Commerce, which belongs to the Zacks Banks - Midwest industry, posted revenues of $498.91 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 2.24%. This compares to year-ago revenues of $445.76 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Commerce shares have added about 11.1% since the beginning of the year versus the S&P 500's gain of 10.6%.
What's Next for Commerce?While Commerce has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Commerce was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.06 on $492.59 million in revenues for the coming quarter and $4.15 on $1.96 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Midwest is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, First Western (MYFW - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on July 23.
This company is expected to post quarterly earnings of $0.56 per share in its upcoming report, which represents a year-over-year change of +115.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
First Western's revenues are expected to be $28.4 million, up 17.4% from the year-ago quarter.
Wall Street looked set for a mixed open Thursday with further yo-yoing in technology stocks amidst a fresh batch of corporate earnings.
Futures pointed to the Dow Jones opening 0.2%, while the S&P 500 was called down 0.2% and the Nasdaq looked set to bear the brunt of the selling, with futures off 0.8% as semiconductor stocks see pressure.
Oil prices were little changed, with West Texas Intermediate trading just below $80 a barrel, despite further escalation in the Middle East.
Iran's military said it had launched missiles and drones at US military positions in Kuwait, Bahrain and Jordan in retaliation for an earlier US strike, while Reuters reported Tehran had instructed Yemen's Houthi movement to prepare to close the Bab el-Mandeb Strait if Washington attacks Iran's power infrastructure, raising the prospect of disruption to a second key global shipping route.
The three major US indexes all finished higher on Wednesday after softer-than-expected producer price inflation reinforced expectations that the Federal Reserve will leave interest rates unchanged later this month.
The Dow rose 150 points, or 0.3%, to 53,141.48, the S&P climbed 0.4% to 7,614.75, and the Nasdaq Composite added 0.6% to close at 25,654.64.
Weakness in Asian semiconductor names seemed to spill into US futures, as markets were unimpressed with Taiwan Semiconductor Manufacturing Co (ADR) (NYSE:TSM) beating expectations with a 77% jump in quarterly profit and upbeat guidance, citing "extremely robust" demand for AI chips. TSMC shares fell about 5% in US premarket trading though.
That follows a similar negative reaction to strong results from Dutch chip equipment maker ASML, highlighting investors' increasingly demanding expectations for AI-linked companies.
Before attention turns to Netflix Inc (NASDAQ:NFLX, XETRA:NFC) after the closing bell, there are a swathe of life science updates ahead of the open.
UnitedHealth Group Inc (NYSE:UNH, XETRA:UNH) rose 6% in premarket trading after the health insurer beat second-quarter earnings expectations and raised its full-year guidance, helped by stronger operational performance despite membership headwinds.
Abbott Laboratories (NYSE:ABT) gained 3.3% as investors welcomed better-than-expected quarterly results and an upbeat outlook.
Merck & Co Inc (NYSE:MRK, XETRA:6MK) added over 1% after the FDA approved its first-in-class cholesterol pill Liprendra, while second-quarter sales edged ahead of forecasts and the drugmaker reiterated its growth outlook.
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) surged almost 34% after agreeing to a $2.8 billion takeover by Eli Lilly, with the deal including additional milestone payments that could take the total value to $3.8 billion.
Prologis Inc (NYSE:PLD) was little moved after the logistics property group beat forecasts on both funds from operations and revenue in the second quarter, signalling resilient demand for warehouse space.
From the financials, State Street Corp (NYSE:STT) climbed after the custodian bank topped expectations for earnings, revenue, net interest income and assets under management in the second quarter.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Income investors chasing headline yields often miss the more powerful compounding engine: the dividend growth rate. A stock yielding 2% today that raises its payout 10% annually will out-earn a 4% yielder that raises 2% within a decade. For July 2026, three large-cap names stand out because each has just delivered a fresh increase, each has explicitly signaled more to come, and each backs the commitment with double-digit or steadily expanding cash flow. Here is the case for buying Visa, NextEra Energy, and Home Depot for growing income.
Visa (V) Visa (NYSE:V | V Price Prediction) sits at the center of the global card-payments duopoly, and management is treating dividend growth as a priority alongside buybacks. The board hiked the quarterly payout 14% in October 2025, lifting it from 59 cents to 67 cents per share. That is the current declared quarterly rate, most recently paid on June 1 against a May 12 ex-dividend date. Shares traded around $356.80 on July 15, 2026, up 2.98% this year and 43.80% across five years.
The bull case is durable double-digit revenue growth funding both the dividend and buybacks. Fiscal Q1 2026 net revenue rose 14.6% year-over-year to $10.90B, non-GAAP EPS came in at $3.17 and operating cash flow expanded 25.7% to $6.78 billion. Visa repurchased roughly 11 million shares for $3.8 billion in the quarter and still has $21.1 billion remaining on its authorization. With a dividend yield near 0.75% and a forward P/E of 23, the payout ratio remains conservative, leaving ample room for continued double-digit hikes. Analyst consensus target sits at $401.16, with 37 Buy or Strong Buy ratings versus three Hold ratings.
Risk: Visa booked a $707 million litigation provision in Q1 tied to the interchange MDL settlement, and regulatory scrutiny of swipe fees remains an overhang.
NextEra Energy (NEE) NextEra Energy (NYSE:NEE) is arguably the cleanest “growing income” story in the utility sector. The company combines Florida Power & Light’s regulated cash flows with the largest renewables development platform in the country, and management has put a specific number on future dividend growth: roughly 10% per year through 2026 off the 2024 base, followed by 6% annually from year-end 2026 through 2028. The quarterly rate has climbed from $0.515 in 2024 to $0.5665 in 2025 to $0.6232 in 2026, with the most recent payment landing June 15, 2026.
Shares traded near $89.34 on July 15 and are up 10.39% year to date and 19.60% over the past year. Q1 2026 adjusted EPS increased 10% year-over-year to $1.09, and NextEra’s renewables arm added a record 4 GW to backlog, bringing total signed backlog to roughly 33 GW. CEO John Ketchum said “NextEra Energy is off to a terrific start… adjusted earnings per share increasing by 10% year-over-year.” Long-term guidance targets 8%+ adjusted EPS CAGR through 2035, giving the dividend ample fundamental cover. The yield sits around 2.67%, well above Visa’s, with analyst target price at $99.25.
July 16 is the Final Day to Tap Into the Lithium Boom (sponsor)
General Motors, POSCO, and 50,000+ everyday investors have already backed lithium producer EnergyX.
Here's why you should do the same before their July 16 investment deadline: lithium prices are up 75% this year, with demand projected to grow a staggering 5X by 2040.
With tech that can recover up to 3X more lithium than traditional methods, EnergyX is preparing to unlock up to 15M+ tons. Become a private-stage EnergyX investor before the July 16 deadline.
Risk: NextEra’s growth requires massive capital spending, with $11.06 billion deployed in Q1 alone, and the company’s Q4 2025 EPS missed consensus by 41%. Any tightening of clean-energy incentives or rising rates could squeeze that model.
Home Depot (HD) Home Depot (NYSE:HD) offers a different flavor of dividend growth: the multi-decade streak. The February raise pushed the quarterly payout from $2.30 to $2.33 per share, extending what management calls its 156th consecutive quarterly dividend. Annualized, that puts the forward payout at $9.32, translating to a yield near 2.05%. Shares traded around $345.42 on July 15, essentially flat year to date at -0.12%, and are down 3.69% over the past year.
The bull case rests on operational discipline and optionality on a housing recovery. Fiscal 2025 revenue reached $164.7 billion (+3.24%), adjusted diluted EPS came in at $14.69, and Q4 adjusted EPS beat expectations at $2.72 versus $2.52. The SRS Distribution and GMS acquisitions extend Home Depot’s reach into the professional contractor market through more than 1,250 SRS locations. Return on equity is an exceptional 128.4%, and analysts carry a target of $370.34 with 22 Buy ratings. CEO Ted Decker credited the year to associates “engaging with our customers and growing market share.”
Risk: Big-ticket demand remains under pressure. Q4 comp customer transactions declined 1.6%, and interest expense from acquisition debt is expected to run around $2.3 billion in fiscal 2026. FY26 adjusted EPS guidance of flat to +4% growth is muted compared with peers, which is why the recent raise was a modest 1.3%.
Three different playbooks, one thesis: each of these companies has just increased its dividend, each has a clearly articulated path to keep doing so, and each generates enough cash to fund the commitment without stretching the payout ratio. For investors focused on the trajectory of income rather than the starting yield, July looks like a reasonable entry point to watch.
Meet America's Newest $1b Unicorn (Sponsor) A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16.
Over 50,000 people already have, along with global giants like General Motors and POSCO.
Here's why there's so much interest: EnergyX's patented tech can recover up to 3X more lithium than traditional methods. That's a big deal, as demand for lithium is expected to 5X current production levels by 2040. Become an early-stage EnergyX shareholder before the 7/16 investment deadline.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
As always, the quarterly earnings were kicked off by the major large-cap money center banks, and as expected they all delivered solid earnings reports. The team at Jefferies remains very positive on the four top companies that beat earnings expectations and, most importantly, provided reassuring forward guidance. Net interest income, or NII, across all banks was impressive, and with the debate over where interest rates will be as we move through the rest of 2026 remaining a wild card for all the financial giants, the second half of the year could prove interesting.
The Jefferies team had this to say when discussing the results:
We’re out with our thoughts following large-cap bank earnings. We highlight that results were largely positive, with all four banks beating Earnings Per Share and Pre-Provision Net Revenue expectations. Loan growth came in modestly above expectations, while deposit trends were generally stable. NII growth remained healthy, supported by strong balance sheet momentum, deposit growth, and fixed-rate asset repricing. Fee income remained constructive, benefiting from strength in payments, treasury services, securities services, wealth management, and transaction banking. Meanwhile, capital markets were a standout performer, driven by robust trading activity, improving investment banking fees, and healthy client engagement.
Here are the four dividend-paying financial giants that Jefferies rates as Buy.
Bank of America Warren Buffett has trimmed his position over the past two years and sold a 50 million shares in the fourth quarter. This quality financial giant remains an exceptional long-term holding with a solid 1.89% dividend yield. Bank of America (NYSE:BAC | BAC Price Prediction) is a bank holding company that reported impressive Q2 results. Berkshire Hathaway owns 513,624,165 shares, which is 7.9% of the portfolio and 7.2% of the float. Berkshire did lower its Bank of America position in Q1 2026, but only modestly. According to the Q1 2026 13F filing, it was reduced by just 0.71%, a very small cut compared to other positions.
The Jefferies analyst noted this:
Bank of America delivered a strong quarter, with core EPS and Pre-Provision Net Revenue ahead of expectations, driven primarily by strength in investment banking and sales & trading. While NII was largely in line, management reiterated growth at the upper end of 6-8% and raised FY26 operating leverage guide to 300-400 bp from >200 bp previously following 2Q’s POL of 640 bp. The return on tangible common equity of 17.0% vs our 16.1% reinforces the earnings power of the franchise.
Its segments include:
Consumer Banking, which offers a range of credit, banking, and investment products and services to consumers and small businesses. Global Wealth & Investment Management (GWIM) comprises two businesses: Merrill Wealth Management, which offers tailored solutions to meet clients’ needs through a comprehensive suite of investment management, brokerage, banking, and retirement products. Bank of America Private Bank provides comprehensive wealth management solutions. Global Banking offers a range of lending-related products and services, including integrated working capital management and treasury solutions, as well as underwriting and advisory services. Global Markets offers sales and trading services, as well as research services, to institutional clients across fixed income, credit, currency, commodity, and equity markets. The Jefferies price target is $75.
Citigroup This money-center giant pays a solid 1.64% and could be poised to deliver continued upside. Citigroup (NYSE:C) is a global diversified financial services holding company. The Jefferies team had this to say when discussing the second-quarter results:
Citi delivered a strong quarter, with core earnings per share and pre-provision net revenue ahead of expectations, driven by stronger-than-expected NII, Markets, and Investment Bank results. Still, the expense outlook was worse than expected, as the return on tangible common equity guide for FY26 was reiterated at 10-11% despite 1H’26 ROTCE trending at 13%. Revenue outperformance could be offset by $5 billion of spending pulled forward that was originally planned for ’27/’28 related to US Card, growth, and productivity initiatives.
The company’s segments include:
Services Markets Banking Wealth U.S. Personal Banking (USPB) The Services segment includes Treasury and Trade Solutions (TTS) and securities services. TTS provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions, and public sector organizations.
The Markets segment provides corporate, institutional, and public-sector clients worldwide with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities.
The Banking segment includes investment banking, which supports client capital-raising needs to help strengthen and grow their businesses.
The Wealth segment includes Private Bank, Wealth at Work, and Citigold, and provides financial services to a range of client segments.
The USPB segment includes branded cards and retail services.
July 16 is the Final Day to Tap Into the Lithium Boom (sponsor)
General Motors, POSCO, and 50,000+ everyday investors have already backed lithium producer EnergyX.
Here's why you should do the same before their July 16 investment deadline: lithium prices are up 75% this year, with demand projected to grow a staggering 5X by 2040.
With tech that can recover up to 3X more lithium than traditional methods, EnergyX is preparing to unlock up to 15M+ tons. Become a private-stage EnergyX investor before the July 16 deadline.
Jefferies has a $165 target price for the shares.
Goldman Sachs The white-glove banking giant delivered exceptional results and pays a 1.47% dividend. Goldman Sachs (NYSE:GS) is a global financial institution that delivers a range of financial services to a large and diversified client base, including corporations, financial institutions, governments, and individuals.
The Jefferies team said this:
Following 2Q26 results, our EPS estimates for the second half of 2026 and FY2027 increase by 9% and 8%, respectively, following a record 1H26 in both markets and advisory. Record equities revenues, all-time-high prime balances, accelerating large-cap M&A, and a five-year-high backlog provide strong support for continued earnings momentum.
Its segments include:
Global Banking & Markets Asset & Wealth Management Platform Solutions The Global Banking & Markets segment offers a range of services, including financing, advisory services, risk distribution, and hedging for its institutional and corporate clients. It facilitates client transactions and makes markets in fixed income, equity, currency, and commodity products.
The Asset & Wealth Management segment manages assets and offers investment products across all asset classes to a diverse client base. It also provides investment and wealth advisory solutions.
The Platform Solutions segment includes consumer platforms, such as partnerships offering credit cards and point-of-sale financing, as well as transaction banking and other platform businesses.
Jefferies has set a price target of $1,299 for the shares.
Wells Fargo With some difficult years in the rearview mirror, this bank could be one of the best values in the financial sector, and pays a 2.11% dividend. Wells Fargo (NYSE:WFC) is a financial services company. The company provides a diversified set of banking, investment, and mortgage products and services, as well as consumer and commercial finance, to individuals, businesses, and institutions.
Jefferies analysts noted this:
WFC posted a headline beat on strong fee income and continued expense discipline, and reiterated its FY26 NII and expense guidance. Despite a solid quarter, shares traded lower amid a net interest margin outlook that fell short of expectations and rising deposit costs. NIM compressed as expected, down 4 bp, in line with the guide, but better-than-expected AEA growth drove a modest NII beat. IB deposit costs rose 9 bps Q/Q, with continued pressure expected in 2H’26 as IB outpaces NIB growth.
Wells Fargo operates through four segments:
Consumer Banking and Lending Commercial Banking Corporate and Investment Banking Wealth & Investment Management The company provides consumer financial products and services, including checking and savings accounts, credit and debit cards, and auto, residential mortgage, and small business lending.
In addition, the company offers financial planning, private banking, investment management, and fiduciary services. It also provides financial solutions to businesses through products and services, including traditional commercial loans and lines of credit, letters of credit, asset-based lending and leasing, trade financing, treasury management, and investment banking services.
The Jefferies target price is $100.
Meet America's Newest $1b Unicorn (Sponsor) A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16.
Over 50,000 people already have, along with global giants like General Motors and POSCO.
Here's why there's so much interest: EnergyX's patented tech can recover up to 3X more lithium than traditional methods. That's a big deal, as demand for lithium is expected to 5X current production levels by 2040. Become an early-stage EnergyX shareholder before the 7/16 investment deadline.
Americká společnost Google ze skupiny Alphabet bude muset podle nových požadavků Evropské unie umožnit společnosti OpenAI i dalším konkurentům v oblasti umělé inteligence (AI) a internetových vyhledávačů přístup ke svým službám. Ve svém rozhodnutí o tom dnes informovala Evropská komise (EK). Opatření má zajistit dodržování pravidel, jejichž cílem je omezit v EU tržní sílu velkých technologických firem. Google s tím nesouhlasí.
Evropská komise dnes vůči společnosti Google přijala dvě sady závazných opatření, která upřesňují její povinnosti podle nařízení o digitálních trzích (DMA). Cílem první sady opatření je zajistit, aby konkurenční služby založené na umělé inteligenci mohly za stejných podmínek jako vlastní služby AI firmy Google, například Gemini, využívat funkce zařízení s operačním systémem Android. Druhá sada opatření má vyrovnat konkurenční podmínky tím, že umožní internetovým vyhledávačům třetích stran přístup k datům z vyhledávání, která je v takovém rozsahu schopen shromažďovat pouze Google Search.
Google v reakci zopakoval své výhrady vůči změnám, které Evropská unie nařizuje. "Dnešní rozhodnutí mohou oslabit zásadní ochranná opatření v oblasti soukromí a bezpečnosti pro miliony Evropanů," uvedl v e-mailovém prohlášení zaslaném agentuře Reuters právník Googlu Kent Walker. "Opakovaně jsme navrhovali řešení, která chrání uživatele a zároveň naplňují cíle DMA. Tato rozhodnutí však přehlížejí rozsáhlé důkazy o tom, že mohou uživatelům způsobit újmu," dodal.
Komise uvedla, že Google zpřístupní konkurentům v oblasti umělé inteligence 11 funkcí operačního systému Android, aby mohli využívat jeho klíčové funkce a lépe konkurovat službě Gemini od Googlu.
V praxi to znamená, že uživatelé budou moci hlasovým povelem aktivovat konkurenčního asistenta AI podobně, jako dnes používají příkaz "Hey Google", například k objednání taxi nebo vyhledávání informací o různých místech. Tyto změny budou uživatelům dostupné od července 2027 v příští verzi systému Android.
Opatření podle EK obsahují důkladná ochranná opatření na ochranu soukromí uživatelů i bezpečnosti jejich zařízení. Google navíc zpřístupní zmíněných 11 funkcí pouze těm konkurentům, kteří splní stanovené požadavky na bezpečnost a ochranu soukromí.
Rozhodnutí EU zároveň Googlu ukládá povinnost sdílet s OpenAI a dalšími chatboty s prvky AI vybavenými funkcí internetového vyhledávání data, která Google využívá ke zlepšování vlastního vyhledávače. Sdílená data však budou předána v anonymizované podobě.
"Díky těmto opatřením doufáme, že vzniknou nové alternativy ke službě Google Search i ke službám AI od Googlu, jako je Gemini, a že uživatelé v Evropské unii získají širší výběr dostupných služeb," uvedla místopředsedkyně EK pro technologickou suverenitu, bezpečnost a demokracii Henna Virkkunenová. "Vyzýváme všechny vývojáře, malé i velké, aby využili těchto nových příležitostí, které podle nás přinesou užitek i samotným uživatelům," dodala.
The company logo for Snowflake Inc. is displayed on a banner to celebrate the company's IPO at the New York Stock Exchange (NYSE) in New York, U.S., September 16, 2020. REUTERS/Brendan... Purchase Licensing Rights, opens new tab Read more
CompaniesJuly 16 (Reuters) - Snowflake (SNOW.N), opens new tab on Thursday unveiled a compensation package worth up to roughly $448 million for CEO Sridhar Ramaswamy, hinging on the cloud-based data analytics platform's market value almost doubling to $184 billion in seven years.
Ramaswamy's award, totaling 1 million shares, is structured into five tranches, each with escalating stock price milestones, and is designed to retain him as CEO until September 15, 2030.
Learn about the latest breakthroughs in AI and tech with the Reuters Artificial Intelligencer newsletter. Sign up here.
Snowflake has been benefiting from clients shifting their workloads to its cloud platform as they invest to develop AI tools.
The company's stock price would need to climb to $531 by July 15, 2033 from Wednesday's closing price of $271.87 for the final tranche, adding up to $100 billion to its market capitalization.
Snowflake offers a platform where clients store and integrate their data in one place to generate business insights, build AI tools and solve operational problems.
Ramaswamy must remain CEO through September 15, 2029 for the first two tranches and September 15, 2030 for the last three to meet the service-based requirement, the company said.
The compensation package also includes clawback clauses for misconduct or accounting restatements, according to a regulatory filing.
Snowflake shares have risen about 24% this year.
In May, the company raised its annual product revenue forecast and announced a five-year deal worth $6 billion with Amazon Web Services (AMZN.O), opens new tab to use AWS's Graviton processors and AI infrastructure.
Reporting by Jaspreet Singh in Bengaluru; Editing by Sahal Muhammed
Our Standards: The Thomson Reuters Trust Principles., opens new tab
On July 16, 2026, U.S. Bancorp (USB) released its 8-K filing, showcasing a solid fiscal performance in the second quarter of 2026. The bank reported net income
U.S. Bancorp (USB - Free Report) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.11 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +5.47%. A quarter ago, it was expected that this company would post earnings of $1.14 per share when it actually produced earnings of $1.18, delivering a surprise of +3.51%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
U.S. Bancorp, which belongs to the Zacks Banks - Major Regional industry, posted revenues of $7.71 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.26%. This compares to year-ago revenues of $7 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
U.S. Bancorp shares have added about 18.1% since the beginning of the year versus the S&P 500's gain of 10.6%.
What's Next for U.S. Bancorp?While U.S. Bancorp has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for U.S. Bancorp was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.31 on $7.85 billion in revenues for the coming quarter and $5.11 on $30.65 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Major Regional is currently in the top 11% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Fifth Third Bancorp (FITB - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on July 17.
This company is expected to post quarterly earnings of $0.98 per share in its upcoming report, which represents a year-over-year change of +8.9%. The consensus EPS estimate for the quarter has been revised 0.4% higher over the last 30 days to the current level.
Fifth Third Bancorp's revenues are expected to be $3.25 billion, up 44.8% from the year-ago quarter.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
M&T Bank Corp (NYSE:MTB) reported upbeat earnings for the second quarter on Wednesday.
The company posted quarterly earnings of $5.35 per share which beat the analyst consensus estimate of $4.66 per share. The company reported quarterly sales of $2.532 billion which beat the analyst consensus estimate of $2.464 billion.
M&T Bank shares rose 2.8% to close at $248.53 on Wednesday.
These analysts made changes to their price targets on M&T Bank following earnings announcement.
Baird analyst David George maintained the stock with a Neutral and raised the price target from $240 to $250. Barclays analyst Jason Goldberg maintained the stock with an Equal-Weight rating and raised the price target from $236 to $267. Keefe, Bruyette & Woods analyst David Konrad maintained the stock with a Market Perform and boosted the price target from $242 to $250. Considering buying MTB stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
PHOENIX--(BUSINESS WIRE)--First Solar, Inc. (NASDAQ: FSLR) (the “Company”) will report financial results for the second quarter ended June 30, 2026, after the market closes on Thursday, July 30, 2026. Conference Call Details are as follows: Date: Thursday, July 30, 2026 Time: 4:30 PM ET Live Webcast: investor.firstsolar.com Webcast Replay: Available through Saturday, August 29, 2026 Investors section of the Company's website approximately two hours after the call About First Solar, Inc. First S.
MILPITAS, Calif.--(BUSINESS WIRE)--SolarEdge Technologies, Inc. (NASDAQ: SEDG), a global leader in smart energy technology, will report financial results for the second quarter ended June 30, 2026, before market open on Wednesday, August 5, 2026. Management will host a conference call at 8:00 A.M. ET on Wednesday, August 5, 2026, to discuss these results. The call will be available live to interested parties by dialing: United States/Canada Toll Free: +1 800-347-6865 International Toll: +1 203-.
Today, Dollar General (NYSE: DG) announced an additional $1 million donation to [url="]Feeding America[/url]Â to extend its ongoing partnership, helping suppo
I rate Duke Energy a buy, driven by structural EPS growth from data-center demand and substantial signed load agreements. DUK's $103 billion investment plan through 2030, with ~7.6 GW of signed agreements and ~5 GW under construction, underpins credible long-term earnings acceleration. Regulatory and funding risks remain, but recent settlements and proactive capital planning narrow the downside while supporting the investment case.
NEW YORK--(BUSINESS WIRE)--Lyft (NASDAQ: LYFT) and Curb, the leading ride-hailing platform for licensed taxis, today announced the expansion of their strategic partnership to New York City, the largest taxi market in the United States. Eligible Lyft riders in New York City can now be matched with a licensed taxi through Curb Flow, Curb's open API that aggregates ride demand into a single network, directly through the Lyft app they already use.The New York City expansion follows launches in Los A.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Considering buying ETSY stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Key Takeaways Albemarle is expanding lithium conversion capacity to capture rising demand.ALB is seeing higher Energy Storage volumes, supported by integrated conversion facilities.ALB's 2026 EPS estimate has trended higher over the past 60 days, with sharp year-over-year expected growth. Albemarle Corporation (ALB - Free Report) is strategically executing its projects aimed at boosting its global lithium conversion capacity. The market for lithium batteries and energy storage remains strong, offering significant opportunities for the company to develop innovative products and expand capacity.
ALB remains focused on investing in high-return projects to drive productivity. Healthy customer demand, capacity expansion and plant productivity improvements are supporting its volumes. ALB saw higher sales volumes (up 14% year over year) in its Energy Storage unit in the first quarter on the strength of its integrated conversion facilities.
The Salar yield improvement project in Chile has achieved a 50% operating rate, and the ramp-up continues to deliver encouraging outcomes. ALB has started the environmental permitting process for a commercial direct lithium extraction project at Salar de Atacama. The ramp-up at the Meishan lithium conversion facility in China is also progressing ahead of schedule. The company’s volumes are expected to continue to be supported by these capacity expansion actions going forward.
Among its peers, Sociedad Quimica y Minera de Chile S.A. (SQM - Free Report) has a robust balance sheet and generates strong cash flows, which allow it to make investments in driving production capacity. SQM logged strong lithium sales volumes of 69,000 metric tons in the first quarter. The Nova Andino Litio business recorded roughly 19% higher volumes compared to the prior-year quarter, driven by capacity expansion actions. SQM is operating at full capacity at the Mt. Holland mine and concentrator in Australia and continues to ramp up the Kwinana refinery.
Rio Tinto Group (RIO - Free Report) is making progress with its high-value lithium projects. The fully owned Rincon Lithium Project in Argentina remains on track with commissioning of the starter plant already being completed and ramp-up currently in progress, with full capacity expected by the end of 2026. The Fénix expansion project and Sal de Vida in Argentina, with a capital cost of $0.7 billion each, are mechanically complete with first production expected in second-half 2026.
The Nemaska Lithium project, in which Rio Tinto now holds a 53.9% stake with the Government of Québec retaining the balance, is a fully integrated spodumene-to-lithium hydroxide development project comprising the lithium hydroxide plant in Bécancour and the Whabouchi spodumene mine with a production capacity of 32,000 tons. RIO initially acquired a 50% interest in Nemaska Lithium through the buyout of Arcadium in March 2025.
ALB’s Price Performance, Valuation & EstimatesAlbemarle has gained 64.7% in the past year compared with the Zacks Chemical - Diversified industry’s decline of 2.8%.
Image Source: Zacks Investment Research
ALB is currently trading at a forward price-to-sales ratio of 2.32, above the industry. It carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ALB’s 2026 earnings implies a year-over-year rise of 1,753.2%. The EPS estimates for 2026 have been trending higher over the past 60 days.
Memory has emerged as one of the biggest bottlenecks in artificial intelligence (AI) data centers, which explains why the demand for these chips has simply taken off in recent years.
In fact, memory demand is so strong that the ongoing supply shortage in this industry is anticipated to last beyond 2030. Not surprisingly, investors have been buying memory stocks, such as Micron Technology (MU 3.88%) and Sandisk, hand over fist over the past year. However, there is a new addition to this list following the U.S. listing of South Korean memory giant SK Hynix (SKHY 7.84%).
This Micron competitor could become one of the biggest winners of the AI-fueled memory boom. Importantly, U.S. investors can now easily invest in this semiconductor stock by buying its Nasdaq-listed American Depository Receipts (ADRs). Let's see why doing so could turn out to be a smart move.
Image source: Getty Images.
SK Hynix is bigger than Micron Micron has been one of the most sought-after memory manufacturers for investors, primarily due to its red-hot revenue and earnings growth. This explains why Micron stock has jumped by a stunning 689% over the past year. SK Hynix, however, has also witnessed a phenomenal 606% rise on the Korean stock market over the past year.
Today's Change
(
-7.84
%) $
-13.83
Current Price
$
162.63
That's not surprising, as it is one of the biggest players in the memory chip market. SK Hynix has been benefiting from rapidly rising prices and a growing appetite for dynamic random-access memory (DRAM) and NAND flash chips. Its operating profit rose by 5x year over year in the first quarter of 2026, while revenue nearly tripled. The company's operating margin also reached a record 72% during the quarter.
Micron's non-GAAP operating margin, meanwhile, landed at 81.2% in the most recent quarter. However, SK Hynix seems well-positioned to bridge the margin gap with Micron owing to its higher market share. According to Counterpoint Research, SK Hynix's DRAM market share was 29% in the first quarter of 2026, seven points higher than Micron's share. The Korean behemoth enjoyed a much larger share of 58% in high-bandwidth memory (HBM), well above Micron's 21%.
Investors should note that HBM demand has been growing exponentially, as this type of memory helps transport massive data sets in AI chip clusters and data centers in an energy-efficient manner. HBM plays a critical role in ensuring that AI accelerator chips don't waste time and energy waiting for data. So, it is easy to see why HBM demand is so strong that the price of these chips is poised to double in 2027, according to DigiTimes.
SK Hynix's position as the leading HBM vendor suggests that its terrific revenue and earnings growth are poised to continue. What's more, SK Hynix holds an 18% market share in NAND flash storage chips, above Micron's 13%. This is another terrific reason to buy SK Hynix stock. After all, NAND flash prices are projected to jump by a whopping 234% in 2026, according to Gartner.
SK Hynix CEO Kwak Noh-Jung recently noted that the memory shortage could worsen in 2027, suggesting prices could continue to rise. He also noted that robust customer demand for memory chips and capacity constraints will ensure that demand for memory continues to outstrip supply beyond 2030.
All this suggests that buying this AI stock could be one of the smartest moves you can make right now, especially considering that SK Hynix is extremely undervalued right now.
This memory stock is about to go parabolic We have already seen that SK Hynix stock has soared impressively over the past year. However, it isn't done soaring yet. Analysts are anticipating a 429% increase in its earnings per share (EPS) in 2026 to 319,109.97 South Korean won, according to Yahoo! Finance consensus estimates, which translates into $214.21 per share at the current exchange rate. However, as each ADR of SK Hynix represents a tenth of its common share, the EPS per ADR would be around $21.42 based on the converted amount.
SK Hynix is trading at 22.3 times trailing earnings, a discount to the tech-focused Nasdaq-100 index's average earnings multiple of 34.5. Assuming it trades at a discounted 20 times earnings at the end of 2026 and its EPS per ADR lands at $21.42, its stock price could reach $428 over the next few months.
That's just over 2x SK Hynix's current stock price, indicating that investors can buy this potential multibagger at an attractive valuation right now.
Large language model (LLM) training was the first big phase of artificial intelligence (AI), but the inference market promises to eventually become the larger market. While AI model training is compute-heavy, inference tends to be much more reliant on fast access to memory.
That is one of the reasons why demand for high-bandwidth memory (HBM), a special form of DRAM (dynamic random access memory) packaged with graphics processing units (GPUs) and other AI chips to optimize performance, has been skyrocketing. It is also one of the reasons why Micron Technology (MU 3.88%) stock has the potential to double from here.
Image source: The Motley Fool.
A cheap stock with big potential Trading at a forward price-to-earnings (P/E) ratio of just 6.5 times fiscal 2027 analyst estimates, Micron's stock is far from expensive and has plenty of room to run if the current memory supercycle lasts longer than investors think. That is just what rival SK Hynix predicted, with its CEO saying that 2027 will be the most supply-constrained year the industry has ever seen and that supply will not be able to catch up with demand until 2030 or beyond.
That type of dynamic is not currently priced into the market, and high DRAM prices could be here to stay. The reason for this is quite simple. Demand for HBM is skyrocketing, in large part due to inference, and hyperscalers (owners of large data centers) have shown no signs of slowing their spending on AI infrastructure.
Meanwhile, both HBM and advanced logic chips, like GPUs, need more extreme ultraviolet lithography (EUV) machines to increase capacity. There is only one company in the world that makes these systems, ASML, and it can only produce so many per year.
Today's Change
(
-3.88
%) $
-35.04
Current Price
$
869.24
In addition, HBM can require three times or more wafer capacity than ordinary DRAM. This means that even as DRAM wafer capacity increases, overall supply still isn't keeping pace. So while the big three DRAM makers are all working to increase capacity, there are built-in constraints that limit their ability to add a large amount of capacity quickly. This should keep DRAM prices high, and DigiTimes has reported that HBM prices could more than double next year.
If DRAM prices remain elevated into 2030 and beyond, it would be easy to see Micron's stock potentially doubling from here. It has entered into long-term supply agreements for the first time, and these agreements now cover 40% of its revenue. That visibility, along with an extended memory supercycle, should see both earnings continue to rise and its multiple expand. That makes it a top AI stock to consider.
BOISE, Idaho, July 16, 2026 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq: MU) has completed Strategic Customer Agreements (SCAs) with key Tier 1 suppliers and ecosystem partners supporting the global automotive industry and automotive manufacturers.
Automotive platforms require consistent, high-quality component supply over extended lifecycles, making continuity and reliability of memory and storage a crucial priority for vehicle production and delivery at scale. Together, the companies – Qualcomm, Visteon, HARMAN, JOYNEXT, DENSO, Astemo and Hyundai Mobis – represent critical suppliers of the technologies that support the automotive ecosystem.
With more than 30 years of leadership in the automotive industry, Micron appreciates the importance of these partnerships. Automotive OEMs rely on memory and storage solutions to support next-generation in-vehicle infotainment, advanced driver assistance and connectivity systems, as well as increasing levels of intelligence in the vehicle. Consumers recognize the value of intelligent in-cabin experiences and higher levels of autonomous safety features enabled by advanced driver assistance systems. These agreements are designed to support long-term access to advanced memory and storage solutions as the automotive industry shifts toward increasingly sophisticated AI-enabled vehicles.
The SCAs provide Micron, as well as these valued partners, with greater visibility for optimized production planning as well as increased collaboration on future memory and storage requirements. By establishing greater certainty around supply and pricing, the agreements support investments in the technology development, qualification and manufacturing capacity required for future vehicle platforms.
Increased visibility and strategic planning are critical for this segment, balancing traditionally longer product lifecycles and rigorous qualification standards with a faster adoption of advanced technology.
“The next phase of automotive innovation will depend on the strength of the ecosystem behind it,” said Sanjay Mehrotra, chairman, president and CEO of Micron Technology. “As vehicles become increasingly intelligent, memory and storage are critical enablers of technology experiences that consumers demand. These SCAs with leading automotive technology partners will help ensure that advanced vehicle platforms have the memory and storage capabilities required to deliver richer, safer and more intelligent experiences.”
“As vehicles become increasingly software-defined, automakers need technology platforms that bring together high-performance compute, connectivity, memory and storage,” said Cristiano Amon, President and CEO, Qualcomm Incorporated. “We work closely with automakers and Tier 1 suppliers to deliver advanced digital cockpit, driver assistance and connectivity solutions designed to support new capabilities over long vehicle lifecycles. Working with Micron helps us give customers the strong technology foundation they need as vehicles become more intelligent and connected.”
“Consumers increasingly expect their vehicles to deliver the intuitive, personalized and connected experiences that match the rest of their digital lives,” said Christian Sobottka, Chief Executive Officer and President, Automotive Division, HARMAN. “Delivering on those expectations at automotive scale requires close collaboration across the technology ecosystem. By working with key technology partners like Micron, we are helping strengthen the resilient memory and storage foundation needed to reliably deliver increasingly intelligent, software-defined vehicle platforms. This helps give automakers greater confidence as we bring differentiated, road-ready in-cabin experiences to market.”
“Automakers are accelerating the development of intelligent vehicle platforms that rely on advanced driver assistance capabilities to enhance safety and driver confidence,” said Lee Gyu-suk, President and CEO of Hyundai Mobis. “Supporting these platforms requires long-term technology planning and a resilient supply ecosystem. Through our relationship with Micron, we are helping build the foundation needed for future ADAS and software-defined vehicle architectures.”
“Advanced digital cockpit experiences depend on high-performance memory and storage,” said Sachin Lawande, President and Chief Executive Officer of Visteon. “Our collaboration with Micron helps support the next generation of connected in-vehicle experiences.”
“To realize a safer and more secure mobility society, the automotive industry must continue advancing the intelligence and capabilities of the systems that support drivers in navigating the road safely,” said Shinnosuke Hayashi, President and CEO of DENSO Corporation. “Partnerships across the automotive ecosystem play an important role in ensuring those technologies can scale to meet the industry's evolving needs.”
Underpinned by Micron's continued global investment in automotive memory and storage technology, manufacturing scale and customer engagement, Strategic Customer Agreements help strengthen relationships across the automotive ecosystem while providing greater visibility into future technology and supply requirements.
These agreements are among the SCAs discussed on Micron’s fiscal third-quarter 2026 financial conference call.
About Micron Technology, Inc.
Micron Technology, Inc. is an industry leader in innovative memory and storage solutions, accelerating intelligence to enrich life for all. With a relentless focus on our customers, technology leadership and manufacturing and operational excellence, Micron delivers a rich portfolio of high-performance DRAM, NAND and NOR memory and storage products. Every day, the innovations that our people create fuel the data economy, enabling advances in artificial intelligence (AI) and compute-intensive applications that unleash opportunities — from the data center to the intelligent edge and across the client and mobile user experience. To learn more about Micron Technology, Inc. (Nasdaq: MU), visit micron.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the anticipated benefits of the collaboration. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially. Please refer to the documents Micron files with the Securities and Exchange Commission, specifically its most recent Form 10-K and Form 10-Q. These documents contain and identify important factors that could cause actual results to differ materially from those contained in these forward-looking statements. These certain factors can be found at https://investors.micron.com/risk-factor. Although Micron believes that the expectations reflected in the forward-looking statements are reasonable, Micron cannot guarantee future results, levels of activity, or achievements. Micron is under no duty to update any of the forward-looking statements after the date of this press release to conform these statements to actual results.
Micron Technology on Thursday signed long-term agreements with automotive suppliers, including chip designer Qualcomm and audio products maker Harman, to secure memory and storage components that powers AI-enabled vehicles.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
At $905, Micron Technology (NASDAQ:MU | MU Price Prediction) shows growing valuation risk. The memory maker has been the single most spectacular AI-adjacent trade of the past year, and that is exactly the problem at today’s quote.
Micron is the only U.S.-based maker of DRAM and NAND memory, and it now sells high-bandwidth memory (HBM) next to every leading-edge AI accelerator. Cloud Memory did $13.769 billion in Q3, Core Data Center added $11.524 billion, and Mobile and Client matched at $11.521 billion. Reported gross margin hit 84.6%, up from 37.7% a year earlier.
The stock has risen from roughly $119.92 a year ago to $904.28, and has pulled back 16.87% in the past month from above $1,087. The question now is whether that pullback is a pause or the start of something bigger.
Why the Bulls Still Own This Trade Q3 revenue landed at $41.456 billion, beating consensus by 17.60%, and non-GAAP EPS of $25.11 beat by 23.79%. Q4 guidance calls for $50 billion in revenue and $31 in EPS at the midpoint, with gross margin near 86%.
Management has signed 16 Strategic Customer Agreements carrying roughly $100 billion in floor-priced revenue over five years, backed by $22 billion in customer cash deposits and letters of credit. CEO Sanjay Mehrotra says HBM4 12-high is ramping twice as fast as HBM3E, and Wall Street’s consensus target of $1,486 implies substantial upside.
Why $905 Is the Wrong Price Three risks weigh on that story at $905.
HBM execution: HBM4 is generating over $1 billion in quarterly revenue with a single lead customer, and HBM4E volume production is not slated until calendar 2027. Any yield stumble, qualification delay, or lost socket resets the entire margin narrative.
Memory cyclicality: DRAM prices rose in the low-60% range and NAND in the mid-80% range sequentially in Q3. Double-ordering likely inflates those numbers, and SCA ceilings pinned at current-quarter market prices limit further spot upside while doing nothing to prevent normalization in the other 60% of revenue. Capex in a hawkish backdrop: Full-year FY2026 capex is guided to roughly $27 billion, with fiscal 2027 quarterly spending running above the Q4 pace. The 10-year Treasury sits at 4.58%, in the 98th percentile of the past year, as Micron writes checks for Idaho, New York, Taiwan, and Singapore fabs.
The Case for Waiting Micron will almost certainly print the guided Q4, order books stretch into 2027, and the SCAs make a 2016-style price crash unlikely. But management just admitted “we are at margin levels where incremental price yields less gross margin expansion” and flagged a $1 billion opex increase for FY2027. Existing holders face a different calculus than new buyers at $905, who would be underwriting a second leg the company itself is guiding to moderate.
July 16 is the Final Day to Tap Into the Lithium Boom (sponsor)
General Motors, POSCO, and 50,000+ everyday investors have already backed lithium producer EnergyX.
Here's why you should do the same before their July 16 investment deadline: lithium prices are up 75% this year, with demand projected to grow a staggering 5X by 2040.
With tech that can recover up to 3X more lithium than traditional methods, EnergyX is preparing to unlock up to 15M+ tons. Become a private-stage EnergyX investor before the July 16 deadline.
What the Stock Says Micron trades at $904.28, against a consensus analyst target of $1,486, implying meaningful upside if targets are met. Forward P/E is 6, trailing P/E 21, and a PEG of 0.14.
Coverage is lopsided: 9 Strong Buy, 31 Buy, 4 Hold, 0 Sell, and 1 Strong Sell. Shares are up 217.03% year to date and 654.1% over one year, versus roughly 10.6% for the S&P 500 YTD.
MU is off 4.69% on the week, 16.87% on the month, and fell 8.02% in the most recent session. The 50-day moving average of $907.42 is now essentially the price.
Why $905 Looks Stretched The path to further downside is short. Q4 will almost certainly beat, but the guided 86% gross margin is the ceiling by management’s own admission. As pricing moderates through calendar 2026, the market will re-rate a business that grew revenue 345.72% year over year off a depressed base. Forward P/E of 6 assumes those earnings hold.
Concentration risk is acute. HBM4 revenue depends on one lead customer. Any AI capex hiccup at a single hyperscaler reprices 33% of Micron’s mix overnight. Layer on $27 billion in fiscal 2026 capex, a $325 million debt prepayment loss last quarter, and a 10-year yield in the 98th percentile, and the financing backdrop for that spend is the worst it has been in a year.
What would invalidate the Sell? A clean HBM4E ramp with a second named lead customer, or SCA revenue crossing 50% of the mix with floor prices materially above prior peak margins. Neither is visible yet. A 654% one-year move already reflects the good news, and the setup asks new buyers to underwrite perfection at the exact moment management is guiding moderation.
History suggests chasing a memory stock the quarter after it prints an 84.9% gross margin has rarely worked out well.
Meet America's Newest $1b Unicorn (Sponsor) A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16.
Over 50,000 people already have, along with global giants like General Motors and POSCO.
Here's why there's so much interest: EnergyX's patented tech can recover up to 3X more lithium than traditional methods. That's a big deal, as demand for lithium is expected to 5X current production levels by 2040. Become an early-stage EnergyX shareholder before the 7/16 investment deadline.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Shares of memory chipmakers are sliding again Thursday morning as fresh worries about Chinese competition ripple through the sector. Micron Technology (NASDAQ:MU | MU Price Prediction) stock is down 5% to $862, while SK Hynix‘s (NASDAQ:SKHY) U.S. ADR is off 7% to $164 in early trading.
SanDisk (NASDAQ:SNDK) shares are also down 7% to $1,505, and Western Digital (NASDAQ:WDC) shares have fallen 7% to $476. The move extends Wednesday’s rout, when the same group dropped 6% to 8%.
That two-day slide follows one of the most explosive runs in recent semiconductor memory. Heading into today, Micron stock was up 217% year to date (YTD), SanDisk shares were up 580% YTD, and Western Digital stock was up 199% YTD.
CXMT’s $8.6 Billion IPO Rattles the Memory Trade The catalyst is a China story. Reportedly, ChangXin Memory Technologies (CXMT), China’s leading DRAM maker and the world’s fourth largest, is set to IPO on Shanghai’s STAR Market on July 27, aiming to raise at least $8.6 billion in Asia’s largest share sale so far this year.
A well-funded domestic DRAM champion expanding capacity is stoking fears of intensifying Chinese memory competition and potential oversupply. That threat lands most directly on the DRAM leaders, which is why Micron and SK Hynix are taking the hardest hits.
So far, this remains a competition and sentiment fear with no confirmed hit yet to any company’s actual results. Per Counterpoint Research, SK Hynix leads the industry with 29% DRAM share and 58% high-bandwidth memory (HBM) share, sitting just ahead of Micron. Industry sources still see the memory shortage lasting beyond 2030.
Peers Follow the Move, ETF Sinks The sector proxy is confirming the damage. The Roundhill Memory ETF (NYSEARCA:DRAM) is down 7% to $53.66, with SK Hynix (weighting 24%) and Micron (24%) driving much of the pain in the fund.
The DRAM ETF is a narrow, volatile thematic fund with real concentration risk in its top holdings, and the ETF isn’t leveraged. Investors sizing their exposure through the fund are getting concentrated results in both directions.
SK Hynix’s ADR carries added ADR-premium risk after only recently beginning to trade on Nasdaq exchange. The listing has already swung from a large surge to sharp drops this week, so SK Hynix stock can move well outside normal single-name ranges intraday.
July 16 is the Final Day to Tap Into the Lithium Boom (sponsor)
General Motors, POSCO, and 50,000+ everyday investors have already backed lithium producer EnergyX.
Here's why you should do the same before their July 16 investment deadline: lithium prices are up 75% this year, with demand projected to grow a staggering 5X by 2040.
With tech that can recover up to 3X more lithium than traditional methods, EnergyX is preparing to unlock up to 15M+ tons. Become a private-stage EnergyX investor before the July 16 deadline.
Secondary drivers today include broad Asian-market volatility, cooling-AI-momentum jitters, and clear profit-taking after parabolic runs. Whether this is a healthy correction or the start of an AI-driven memory bubble bursting is a genuine, polarized debate right now.
Bull vs. Bear on Micron The bull case for Micron is intact on the fundamentals. Micron just reported Q3 FY2026 revenue of $41.5 billion, up 346% year over year (YoY), with GAAP gross margin of 85%, and guided Q4 FY2026 revenue to $50 billion at the midpoint.
CEO Sanjay Mehrotra stated that Micron’s results “reflect the strategic value of memory in the AI era.” On the other hand, the bear case leans on the CXMT threat, memory-industry cyclicality, and rich valuations after enormous gains.
Polymarket traders now put Micron stock in the $840 to $870 range by Friday’s close, with a 63% probability of another down day today. Western Digital is less directly exposed to the DRAM and NAND fight after the SanDisk spinoff, yet Western Digital shares are being pulled down with the group.
What to Watch Next CXMT’s July 27 IPO pricing and any updated color on Chinese memory capacity plans are the next real catalysts. Investors can watch for whether Micron stock holds above $860 into the close.
The Roundhill Memory ETF at $53 and change is a useful tape to track for whether today’s damage stabilizes or spreads to the rest of AI infrastructure. A second red close for the fund this week would suggest that the reset isn’t finished.
Given how violently these names are swinging in both directions, investors should consider keeping their position sizes modest on their memory exposure here. AI-driven memory demand remains real, but the price action is telling traders that valuation and Chinese-competition risks are back in play.
Meet America's Newest $1b Unicorn (Sponsor) A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16.
Over 50,000 people already have, along with global giants like General Motors and POSCO.
Here's why there's so much interest: EnergyX's patented tech can recover up to 3X more lithium than traditional methods. That's a big deal, as demand for lithium is expected to 5X current production levels by 2040. Become an early-stage EnergyX shareholder before the 7/16 investment deadline.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zillow To Contact Him Directly To Discuss Their Options
If you purchased or acquired Class A or Class C Zillow common stock between February 11, 2025 and May 7, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - July 16, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zillow Group, Inc. ("Zillow" or the "Company") (NASDAQ: ZG) (NASDAQ: Z) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Zillow's agreement with Redfin was not a "partnership," but rather an acquisition of Redfin's business; (2) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (3) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (4) as a result, Defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and or lacked a reasonable basis at all relevant times.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Zillow's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Zillow class action, go to www.faruqilaw.com/Z or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Zillow Securities Class Action Lawsuit:
What is the Zillow securities fraud lawsuit about?
The lawsuit alleges Zillow misrepresented its agreement with Redfin as a partnership, understated antitrust and regulatory risks, and downplayed potential legal exposure, making statements about its business and prospects allegedly misleading.
Who may be eligible to participate in the lawsuit?
Investors who purchased or acquired Zillow Class A or Class C common stock (NASDAQ: Z) (NASDAQ: ZG) between February 11, 2025 and May 7, 2026 may be eligible to participate if they suffered losses related to the alleged misconduct.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff represents the interests of the proposed class and helps oversee the litigation. Investors seeking appointment must file a motion with the court by August 10, 2026. Investors can share in any recovery without serving as lead plaintiff.
What should investors do if they purchased Zillow stock during the Class Period?
Investors should review their transaction records, preserve relevant documents, and evaluate their legal options. Those who suffered losses may wish to consult counsel regarding participation in the lawsuit or seeking lead plaintiff status before the deadline.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Zillow securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305343
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired Class A (NASDAQ: ZG) or Class C (NASDAQ: Z) common stock of Zillow Group, Inc. (“Zillow” or the “Company”) between February 11, 2025 and May 7, 2026, inclusive.
Should You Join The Zillow Group Class Action Lawsuit:
Do you, or did you, own shares of Zillow Group, Inc. (NASDAQ: ZG, Z)?Did you purchase your shares between February 11, 2025 and May 7, 2026, inclusive?Did you lose money in your investment in Zillow Group, Inc.?
What To Do Next:
Investors are encouraged to act promptly and submit a form at Zillow Group, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].
If you wish to serve as lead plaintiff for the Class, you must file papers by August 10, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About The Lawsuit:
The lawsuit alleges that defendants made materially false and misleading statements and omissions regarding the Company’s business operations, growth prospects, and financial stability. As a result of these alleged misrepresentations, Zillow common stock traded at artificially inflated prices during the Class Period. When the truth was disclosed, investors allegedly suffered significant losses.
About Bernstein Liebhard:
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
Taiwan Semiconductor delivered stellar Q2 2026 results, with revenues up 34% y/y to $40.2B and robust margin expansion driven by AI demand. TSM's HPC segment grew 47.4% y/y, now 66% of revenues, while advanced 2nm node ramp and aggressive capex underpin its technology leadership. Despite near-term margin dilution from 2nm and elevated capex, I see TSM trading at a 30% discount to fair value ($526/share) and view current weakness as a buying opportunity.
Investors taking profits in AI memory names like SK Hynix (SKHY) and Samsung overseas is something Tom White sees hitting U.S. stocks. TSMC's (TSM) earnings added volatility to the tech trade even after it beat and announced an additional $100 billion investment into the U.S. Tom turns to the healthcare sector by talking about UnitedHealth's (UNH) earnings and how it shows the company "correcting the pains" it brought to investors in 2025.
TSM stock is moving lower. See the chart and price action here. Record Profits, but a Costly Growth PlanIn the second quarter, TSMC’s revenue climbed to $40.2 billion, landing at the high end of guidance and comfortably ahead of Wall Street expectations. The growth was powered by relentless demand for AI processors, which pushed net profit to a record near $22 billion and lifted gross margins to 67.7%, topping management’s own forecast.
On the surface, it was the textbook AI‑hardware beat: strong top‑line growth, expanding profitability and a backlog of orders tied to the biggest technology shift in a generation.
Yet the shares dropped roughly 4.6% in premarket trading as the market zeroed in on the other side of the story — an aggressive capital‑spending ramp that will test investor patience.
Management lifted its 2026 capex guidance to a range of $60 billion-$64 billion, up from a prior range of $52–$56 billion, with most of the incremental spend earmarked for advanced nodes that serve AI and high‑performance computing customers.
The earnings report and capex expansion created a "great quarter, scary spend" dynamic in which investors are being asked to underwrite a multi‑year AI build‑out before the cycle’s durability is fully proven.
Earlier in the AI chip frenzy, the market largely rewarded upside surprises on demand and shrugged off rising capex as the necessary cost of doing business. The reaction to TSM’s latest guidance hints at a transition into a more demanding phase, where questions about payback periods, utilization and long‑run margin trajectories matter as much as headline revenue growth.
The TakeawayTSM remains the foundry king of the AI era, with financials that reflect extraordinary momentum. But the stock’s pullback suggests that, at current valuation levels, investors want a clearer roadmap for how a $60‑plus‑billion capex plan translates into durable returns rather than just a more expensive growth story.
TSM Stock Price Activity: Taiwan Semiconductor stock was down 4.5% at $400.60 during premarket trading Thursday, according to data from Benzinga Pro.
Over the past month, TSM has declined about 8.1% versus a 0.0% decline in the S&P 500 and is up roughly 28% year-to-date compared to the index’s 10.1% gain.
Photo: Kittyfly / Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31 Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%¹ Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58 Abbott returned $2.1 billion to shareholders in the second quarter in the form of dividends and share repurchases , /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2026.
Second-quarter sales increased 13.0 percent on a reported basis and 4.8 percent on a comparable basis. Second-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items. Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%1. Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58. In April, Abbott completed enrollment in its TECTONIC U.S. pivotal trial. This trial is designed to evaluate Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System for treating severe calcification in coronary arteries prior to stent implantation. In April, at the Heart Rhythm Society (HRS) conference, Abbott presented new late-breaking data from four clinical trials that demonstrated strong clinical outcomes across the company's pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios. In May, Abbott announced it secured CE Mark for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes. In May, Abbott completed its submission to the U.S. Food and Drug Administration (FDA) seeking approval for the company's Amulet™ 360 left atrial appendage (LAA) device. In May, the American Cancer Society (ACS) issued updated colorectal cancer (CRC) screening guidelines that reaffirmed Cologuard® and Cologuard Plus® as preferred screening options for adults age 45 and older who are at average risk for CRC. "Our second-quarter results reflect the momentum we are building," said Robert B. Ford, chairman and chief executive officer, Abbott. "We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."
SECOND-QUARTER BUSINESS OVERVIEW
Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
Total Company
Nutrition
Diagnostics
Established
Pharmaceuticals
Medical Devices
U.S.
5,216
871
1,660
—
2,680
International
7,377
1,273
1,432
1,499
3,173
Total reported
12,593
2,144
3,092
1,499
5,853
% Change vs. 2Q25
U.S.
22.0
(9.0)
104.8
n/a
7.0
International
7.5
1.4
5.1
8.4
10.7
Total reported
13.0
(3.1)
42.3
8.4
9.0
Total reported excl. foreign exchange impact
12.2
(3.6)
41.3
8.7
7.9
Comparable sales growth
4.8
(3.6)
2.9
8.7
8.4
U.S.
3.5
(9.0)
4.0
n/a
8.0
International
5.8
0.6
1.6
8.7
8.7
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
Total Company
Nutrition
Diagnostics
Established
Pharmaceuticals
Medical Devices
U.S.
9,490
1,715
2,565
—
5,203
International
14,267
2,446
2,707
2,925
6,189
Total reported
23,757
4,161
5,272
2,925
11,392
% Change vs. 1H25
U.S.
12.4
(10.3)
52.5
n/a
7.4
International
9.3
—
6.4
10.7
14.2
Total reported
10.5
(4.5)
24.7
10.7
11.0
Total reported excl. foreign exchange impact
8.2
(5.6)
22.4
8.9
8.0
Comparable sales growth
4.3
(5.6)
2.4
8.9
8.4
U.S.
3.0
(10.3)
3.0
n/a
8.3
International
5.3
(1.9)
1.6
8.9
8.5
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.
Nutrition
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
Total
Pediatric
Adult
U.S.
871
525
346
International
1,273
500
773
Total reported
2,144
1,025
1,119
% Change vs. 2Q25
U.S.
(9.0)
(10.7)
(6.4)
International
1.4
7.3
(2.0)
Total reported
(3.1)
(2.7)
(3.4)
Total reported excl. foreign exchange impact
(3.6)
(3.1)
(4.0)
Comparable sales growth
(3.6)
(3.1)
(4.0)
U.S.
(9.0)
(10.7)
(6.4)
International
0.6
6.4
(2.8)
Worldwide Nutrition sales decreased 3.1 percent on a reported basis and 3.6 percent on a comparable basis in the second quarter.
Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025. These pricing actions, together with the launch of new products, are contributing to improving performance. Nutrition sales increased $127 million on a sequential basis compared to the first quarter of 2026.
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
Total
Pediatric
Adult
U.S.
1,715
1,036
679
International
2,446
942
1,504
Total reported
4,161
1,978
2,183
% Change vs. 1H25
U.S.
(10.3)
(11.9)
(7.8)
International
—
2.4
(1.5)
Total reported
(4.5)
(5.6)
(3.5)
Total reported excl. foreign exchange impact
(5.6)
(6.4)
(4.9)
Comparable sales growth
(5.6)
(6.4)
(4.9)
U.S.
(10.3)
(11.9)
(7.8)
International
(1.9)
0.7
(3.5)
Diagnostics*
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
Total
Core Laboratory
Cancer Diagnostics
Rapid/Molecular
Diagnostics
U.S.
1,660
377
890
393
International
1,432
1,041
29
362
Total reported
3,092
1,418
919
755
% Change vs. 2Q25
U.S.
104.8
7.5
n/a
(14.5)
International
5.1
3.4
n/a
2.0
Total reported
42.3
4.4
n/a
(7.3)
Total reported excl. foreign exchange impact
41.3
3.2
n/a
(8.0)
Comparable sales growth
2.9
3.2
13.3
(8.0)
U.S.
4.0
7.5
13.3
(14.5)
International
1.6
1.7
13.8
0.5
Worldwide Diagnostics sales increased 42.3 percent on a reported basis and 2.9 percent on a comparable basis in the second quarter.
Worldwide Core Laboratory Diagnostics results were driven by strong growth in the U.S. and Latin America.
Rapid and Molecular Diagnostics results reflect lower sales of respiratory virus tests compared to the prior year.
Cancer Diagnostics results were driven by mid-teens growth of Cologuard, which is benefiting from a growing base of both new and repeat users. Results in the quarter also reflect contributions to growth from the precision oncology and international businesses.
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
Total
Core Laboratory
Cancer Diagnostics
Rapid/Molecular
Diagnostics
U.S.
2,565
724
983
858
International
2,707
1,966
32
709
Total reported
5,272
2,690
1,015
1,567
% Change vs. 1H25
U.S.
52.5
6.0
n/a
(14.1)
International
6.4
6.1
n/a
2.4
Total reported
24.7
6.1
n/a
(7.4)
Total reported excl. foreign exchange impact
22.4
3.2
n/a
(8.8)
Comparable sales growth
2.4
3.2
13.3
(8.8)
U.S.
3.0
6.0
13.2
(14.1)
International
1.6
2.2
16.5
(1.1)
*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.
Established Pharmaceuticals
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
Total
Key Emerging
Markets
Other
U.S.
—
—
—
International
1,499
1,164
335
Total reported
1,499
1,164
335
% Change vs. 2Q25
U.S.
n/a
n/a
n/a
International
8.4
9.8
3.7
Total reported
8.4
9.8
3.7
Total reported excl. foreign exchange impact
8.7
10.7
2.1
Comparable sales growth
8.7
10.7
2.1
U.S.
n/a
n/a
n/a
International
8.7
10.7
2.1
Established Pharmaceuticals sales increased 8.4 percent on a reported basis and 8.7 percent on a comparable basis in the second quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 9.8 percent on a reported basis and 10.7 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions.
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
Total
Key Emerging
Markets
Other
U.S.
—
—
—
International
2,925
2,253
672
Total reported
2,925
2,253
672
% Change vs. 1H25
U.S.
n/a
n/a
n/a
International
10.7
11.3
8.6
Total reported
10.7
11.3
8.6
Total reported excl. foreign exchange impact
8.9
10.1
4.9
Comparable sales growth
8.9
10.1
4.9
U.S.
n/a
n/a
n/a
International
8.9
10.1
4.9
Medical Devices
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
Total
Rhythm
Management
Electro-
physiology*
Heart
Failure
Vascular
Structural
Heart*
Neuro-
modulation
Diabetes
Care
U.S.
2,680
377
420
313
294
225
189
862
International
3,173
366
441
88
509
372
71
1,326
Total reported
5,853
743
861
401
803
597
260
2,188
% Change vs. 2Q25
U.S.
7.0
10.7
15.9
10.9
3.9
(9.8)
(2.1)
8.6
International
10.7
10.0
12.3
3.0
7.5
12.1
14.7
11.7
Total reported
9.0
10.4
14.0
9.0
6.1
2.7
2.0
10.5
Total reported excl. foreign exchange impact
7.9
9.5
13.4
8.7
5.1
1.7
1.2
9.0
Comparable sales growth
8.4
9.5
13.4
8.7
5.1
5.7
1.2
9.0
U.S.
8.0
10.7
15.9
10.9
3.9
(0.9)
(2.1)
8.6
International
8.7
8.3
11.1
1.3
5.8
10.2
11.3
9.2
Worldwide Medical Devices sales increased 9.0 percent on a reported basis and 8.4 percent on a comparable basis in the second quarter.
Sales growth in the quarter was led by low-teens growth in Electrophysiology and high-single-digit growth in Rhythm Management, Diabetes Care, and Heart Failure.
In Diabetes Care, sales of continuous glucose monitors grew 11.0 percent on a reported basis and 9.5 percent on a comparable basis.
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
Total
Rhythm
Management
Electro-
physiology*
Heart
Failure
Vascular
Structural
Heart*
Neuro-
modulation
Diabetes
Care
U.S.
5,203
716
798
605
585
449
366
1,684
International
6,189
711
851
185
995
726
137
2,584
Total reported
11,392
1,427
1,649
790
1,580
1,175
503
4,268
% Change vs. 1H25
U.S.
7.4
11.1
14.8
11.1
6.2
(9.6)
(0.7)
9.2
International
14.2
15.9
15.7
13.5
8.7
18.1
20.4
14.0
Total reported
11.0
13.4
15.3
11.7
7.7
5.7
4.3
12.1
Total reported excl. foreign exchange impact
8.0
10.9
13.0
10.4
5.0
2.6
2.6
8.2
Comparable sales growth
8.4
10.9
13.0
10.4
5.0
6.2
2.6
8.2
U.S.
8.3
11.1
14.8
11.1
6.2
(2.2)
(0.7)
9.2
International
8.5
10.7
11.2
7.8
4.3
12.4
13.2
7.5
*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 and $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology.
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.
Abbott's Financial Guidance
Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1.
Abbott projects full-year 2026 adjusted diluted earnings per share of $5.45 to $5.60.
Abbott projects third-quarter 2026 adjusted diluted earnings per share of $1.38 to $1.46.
Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.
Abbott Declares 410th Consecutive Quarterly Dividend
On June 12, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Aug. 17, 2026, to shareholders of record at the close of business on July 15, 2026.
Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.
— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott's Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million. Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Second Quarter Ended June 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
2Q26
2Q25
% Change
Net Sales
$12,593
$11,142
13.0
Cost of products sold, excluding amortization expense
5,325
4,854
9.7
Amortization of intangible assets
658
420
56.8
Research and development
892
725
22.9
Selling, general, and administrative
4,025
3,091
30.3
Total Operating Cost and Expenses
10,900
9,090
19.9
Operating Earnings
1,693
2,052
(17.5)
Interest expense, net
299
50
n/m
Net foreign exchange (gain) loss
4
(11)
n/m
Other (income) expense, net
(134)
(137)
(2.5)
Earnings before taxes
1,524
2,150
(29.1)
Taxes on Earnings
596
371
60.8
1)
Net Earnings
$928
$1,779
(47.8)
Net Earnings excluding Specified Items, as described below
$2,290
$2,213
3.5
2)
Diluted Earnings per Common Share
$0.53
$1.01
n/m
Diluted Earnings per Common Share, excluding Specified Items, as described below
$1.31
$1.26
4.0
2)
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options
1,743
1,751
NOTES:
See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following section.
1)
2026 Taxes on Earnings includes the recognition of approximately $110 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)
2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.362 billion, or $0.78 per share, for intangible amortization, charges related to acquisitions, legal reserves, investment impairments, and other net expenses.
2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $434 million, or $0.25 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
First Half Ended June 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
1H26
1H25
% Change
Net Sales
$23,757
$21,500
10.5
Cost of products sold, excluding amortization expense
10,215
9,322
9.6
Amortization of intangible assets
1,080
840
28.5
Research and development
1,659
1,441
15.1
Selling, general, and administrative
7,765
6,152
26.2
Total Operating Cost and Expenses
20,719
17,755
16.7
Operating Earnings
3,038
3,745
(18.9)
Interest expense, net
367
99
n/m
Net foreign exchange (gain) loss
(9)
(18)
n/m
Other (income) expense, net
(293)
(264)
10.6
Earnings before taxes
2,973
3,928
(24.3)
Taxes on earnings
968
824
17.5
1)
Net Earnings
$2,005
$3,104
n/m
Net Earnings excluding Specified Items, as described below
$4,312
$4,132
4.4
2)
Diluted Earnings per Common Share
$1.14
$1.77
n/m
Diluted Earnings per Common Share,
excluding Specified Items, as described below
$2.46
$2.35
4.7
2)
Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options
1,745
1,749
NOTES:
See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following section.
1)
2026 Taxes on Earnings includes the recognition of approximately $60 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)
2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $2.307 billion, or $1.32 per share, for intangible amortization, charges related to acquisitions, legal reserves, investment impairments, restructuring, and other net expenses.
2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.028 billion, or $0.58 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Second Quarter Ended June 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
2Q26
As
Reported
(GAAP)
Specified
Items
As
Adjusted
Intangible Amortization
$ 658
$ (658)
$ —
Gross Margin
6,610
697
7,307
R&D
892
(25)
867
SG&A
4,025
(428)
3,597
Other (income) expense, net
(134)
(27)
(161)
Earnings before taxes
1,524
1,177
2,701
Taxes on Earnings
596
(185)
411
Net Earnings
928
1,362
2,290
Diluted Earnings per Share
$ 0.53
$ 0.78
$ 1.31
Specified items reflect intangible amortization expense of $658 million and other net expenses of $519 million associated with acquisitions, legal reserves, investment impairments, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
2Q25
As
Reported
(GAAP)
Specified
Items
As
Adjusted
Intangible Amortization
$ 420
$ (420)
$ —
Gross Margin
5,868
478
6,346
R&D
725
(20)
705
SG&A
3,091
(1)
3,090
Other (income) expense, net
(137)
(1)
(138)
Earnings before taxes
2,150
500
2,650
Taxes on Earnings
371
66
437
Net Earnings
1,779
434
2,213
Diluted Earnings per Share
$ 1.01
$ 0.25
$ 1.26
Specified items reflect intangible amortization expense of $420 million and other net expenses of $80 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
First Half Ended June 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
1H26
As
Reported
(GAAP)
Specified
Items
As
Adjusted
Intangible Amortization
$ 1,080
$ (1,080)
$ —
Gross Margin
12,462
1,129
13,591
R&D
1,659
(49)
1,610
SG&A
7,765
(901)
6,864
Other (income) expense, net
(293)
(34)
(327)
Earnings before taxes
2,973
2,113
5,086
Taxes on Earnings
968
(194)
774
Net Earnings
2,005
2,307
4,312
Diluted Earnings per Share
$ 1.14
$ 1.32
$ 2.46
Specified items reflect intangible amortization expense of $1.080 billion and other net expenses of $1.033 billion associated with restructuring actions, acquisitions, legal reserves, investment impairments, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
1H25
As
Reported
(GAAP)
Specified
Items
As
Adjusted
Intangible Amortization
$ 840
$ (840)
$ —
Gross Margin
11,338
926
12,264
R&D
1,441
(47)
1,394
SG&A
6,152
(11)
6,141
Other (income) expense, net
(264)
(36)
(300)
Earnings before taxes
3,928
1,020
4,948
Taxes on Earnings
824
(8)
816
Net Earnings
3,104
1,028
4,132
Diluted Earnings per Share
$ 1.77
$ 0.58
$ 2.35
Specified items reflect intangible amortization expense of $840 million and other net expenses of $180 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
A reconciliation of the second-quarter tax rates for 2026 and 2025 is shown below:
2Q26
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$ 1,524
$ 596
39.1 %
1)
Specified items
1,177
(185)
Excluding specified items
$ 2,701
$ 411
15.2 %
2Q25
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$ 2,150
$ 371
17.3 %
2)
Specified items
500
66
Excluding specified items
$ 2,650
$ 437
16.5 %
1)
2026 Taxes on Earnings includes the recognition of approximately $110 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)
2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
A reconciliation of the year-to-date tax rates for 2026 and 2025 is shown below:
1H26
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$ 2,973
$ 968
32.5 %
3)
Specified items
2,113
(194)
Excluding specified items
$ 5,086
$ 774
15.2 %
1H25
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$ 3,928
$ 824
21.0 %
4)
Specified items
1,020
(8)
Excluding specified items
$ 4,948
$ 816
16.5 %
3)
2026 Taxes on Earnings includes the recognition of approximately $60 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
4)
2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
Second Quarter Ended June 30, 2026 and 2025
($ in millions)
(unaudited)
2Q26
2Q25
% Change vs. 2Q25
Non-GAAP
Abbott
Reported
Foreign
exchange
Comparable
Revenue
Abbott
Reported
Impact of
acquisition (a)
Impact
of multi-year
agreement (b)
Comparable
Revenue
Reported
Comparable
Total Company
12,593
(86)
12,507
11,142
811
(22)
11,931
13.0
4.8
U.S.
5,216
—
5,216
4,276
786
(22)
5,040
22.0
3.5
Intl
7,377
(86)
7,291
6,866
25
—
6,891
7.5
5.8
Total Diagnostics
3,092
(22)
3,070
2,173
811
—
2,984
42.3
2.9
U.S.
1,660
—
1,660
811
786
—
1,597
104.8
4.0
Intl
1,432
(22)
1,410
1,362
25
—
1,387
5.1
1.6
Total Cancer Diagnostics
919
—
919
—
811
—
811
n/a
13.3
U.S.
890
—
890
—
786
—
786
n/a
13.3
Intl
29
—
29
—
25
—
25
n/a
13.8
Total Medical Devices
5,853
(57)
5,796
5,369
—
(22)
5,347
9.0
8.4
U.S.
2,680
—
2,680
2,503
—
(22)
2,481
7.0
8.0
Intl
3,173
(57)
3,116
2,866
—
—
2,866
10.7
8.7
Total Structural Heart*
597
(6)
591
581
—
(22)
559
2.7
5.7
U.S.
225
—
225
249
—
(22)
227
(9.8)
(0.9)
Intl
372
(6)
366
332
—
—
332
12.1
10.2
*
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 were moved from Structural Heart to Electrophysiology.
a)
The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.
b)
Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.
Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
First Half Ended June 30, 2026 and 2025
($ in millions)
(unaudited)
1H26
1H25
% Change vs. 1H25
Non-GAAP
Abbott
Reported
Impact of
acquisition (a)
Impact
of multi-year
agreement (b)
Foreign
exchange
Comparable
Revenue
Abbott
Reported
Impact of
acquisition (a)
Impact
of multi-year
agreement (b)
Comparable
Revenue
Reported
Comparable
Total Company
23,757
706
(8)
(500)
23,955
21,500
1,518
(46)
22,972
10.5
4.3
U.S.
9,490
681
(8)
—
10,163
8,444
1,470
(46)
9,868
12.4
3.0
Intl
14,267
25
—
(500)
13,792
13,056
48
—
13,104
9.3
5.3
Total Diagnostics
5,272
706
—
(98)
5,880
4,227
1,518
—
5,745
24.7
2.4
U.S.
2,565
681
—
—
3,246
1,682
1,470
—
3,152
52.5
3.0
Intl
2,707
25
—
(98)
2,634
2,545
48
—
2,593
6.4
1.6
Total Cancer Diagnostics
1,015
706
—
(1)
1,720
—
1,518
—
1,518
n/a
13.3
U.S.
983
681
—
—
1,664
—
1,470
—
1,470
n/a
13.2
Intl
32
25
—
(1)
56
—
48
—
48
n/a
16.5
Total Medical Devices
11,392
—
(8)
(306)
11,078
10,264
—
(46)
10,218
11.0
8.4
U.S.
5,203
—
(8)
—
5,195
4,842
—
(46)
4,796
7.4
8.3
Intl
6,189
—
—
(306)
5,883
5,422
—
—
5,422
14.2
8.5
Total Structural Heart*
1,175
—
(8)
(35)
1,132
1,112
—
(46)
1,066
5.7
6.2
U.S.
449
—
(8)
—
441
497
—
(46)
451
(9.6)
(2.2)
Intl
726
—
—
(35)
691
615
—
—
615
18.1
12.4
*
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology.
a)
The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.
b)
Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.
Abbott Laboratories and Subsidiaries
Details of Specified Items
Second Quarter Ended June 30, 2026
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b)
Intangible
Amortization
Other (c)
Total
Specifieds
Gross Margin
$ 32
$ 4
$ 658
$ 3
$ 697
R&D
(10)
—
—
(15)
(25)
SG&A
(42)
(1)
—
(385)
(428)
Other (income) expense, net
1
(1)
—
(27)
(27)
Earnings before taxes
$ 83
$ 6
$ 658
$ 430
1,177
Taxes on Earnings (d)
(185)
Net Earnings
$ 1,362
Diluted Earnings per Share
$ 0.78
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)
Acquisition-related expenses include integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.
b)
Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans.
c)
Other includes $385 million for legal reserves related to an agreed-in-principle settlement, subject to satisfaction of certain contingencies, as well as charges related to investment impairments and incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)
Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Abbott Laboratories and Subsidiaries
Details of Specified Items
Second Quarter Ended June 30, 2025
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b)
Intangible
Amortization
Other (c)
Total
Specifieds
Gross Margin
$ 1
$ 55
$ 420
$ 2
$ 478
R&D
—
(7)
—
(13)
(20)
SG&A
(3)
1
—
1
(1)
Other (income) expense, net
(1)
—
—
—
(1)
Earnings before taxes
$ 5
$ 61
$ 420
$ 14
500
Taxes on Earnings (d)
66
Net Earnings
$ 434
Diluted Earnings per Share
$ 0.25
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)
Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.
b)
Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)
Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)
Reflects the net tax benefit associated with the specified items and the recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Abbott Laboratories and Subsidiaries
Details of Specified Items
First Half Ended June 30, 2026
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b)
Intangible
Amortization
Other (c)
Total
Specifieds
Gross Margin
$ 34
$ 11
$ 1,080
$ 4
$ 1,129
R&D
(11)
(10)
—
(28)
(49)
SG&A
(486)
(34)
—
(381)
(901)
Other (income) expense, net
(1)
(3)
—
(30)
(34)
Earnings before taxes
$ 532
$ 58
$ 1,080
$ 443
2,113
Taxes on Earnings (d)
(194)
Net Earnings
$ 2,307
Diluted Earnings per Share
$ 1.32
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)
Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.
b)
Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.
c)
Other includes $385 million for legal reserves related to an agreed-in-principle settlement, subject to satisfaction of certain contingencies, as well as charges related to investment impairments and incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)
Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Abbott Laboratories and Subsidiaries
Details of Specified Items
First Half Ended June 30, 2025
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b)
Intangible
Amortization
Other (c)
Total
Specifieds
Gross Margin
$ 1
$ 81
$ 840
$ 4
$ 926
R&D
(1)
(23)
—
(23)
(47)
SG&A
(6)
(6)
—
1
(11)
Other (income) expense, net
(25)
—
—
(11)
(36)
Earnings before taxes
$ 33
$ 110
$ 840
$ 37
1,020
Taxes on Earnings (d)
(8)
Net Earnings
$ 1,028
Diluted Earnings per Share
$ 0.58
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)
Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)
Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)
Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.
d)
Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
The market still treats Abbott Laboratories (NYSE:ABT | ABT Price Prediction) like a bond proxy with a stethoscope: baby formula, branded generics, and a metronomic dividend. That framing looks increasingly stale, and the stock’s punishing drawdown has widened the gap between narrative and numbers.
Abbott is a card-carrying S&P 500 Dividend Aristocrat, riding a 54th consecutive year of dividend increases and a 410th consecutive quarterly payout of $0.63 per share. A beta of 0.607 reinforces the “sleep well at night” identity. That reputation is precisely why the transformation underneath it is being underpriced.
A New Growth Engine and a Pivot Hiding in Plain Sight Medical Devices is now the dominant engine, generating $5.54 billion in Q1 2026, up 13.2%. Inside that segment, the FreeStyle Libre continuous glucose monitor franchise cleared $2.08 billion in the quarter, growing 13.8%. CEO Robert Ford is explicit about the runway: “Our assessment of the number of people who should be on a CGM on a global basis is between 70 million and 80 million people. The market today is around 10 to 12 million people.”
Established Pharmaceuticals grew 13.2% and international sales rose 11.3%. Adjusted EPS came in at $1.15, the fourth consecutive beat, with full-year adjusted EPS guidance of $5.38 to $5.58. Abbott remains a compounder still compounding.
On March 23, 2026, Abbott closed its roughly $21 billion acquisition of Exact Sciences, launching a Cancer Diagnostics unit anchored by Cologuard and Cancerguard. Management expects approximately $3 billion of incremental sales in 2026. Ford framed the strategic logic: “About 50 million Americans are not up to date with CRC screening… Cologuard does really well here. Not only is it convenient at home, but its sensitivity at 95% is equivalent to colonoscopy.”
The Mispricing Shares closed most recently at $89.27, down 28.8% year to date and 32.1% over one year. The $116.54 analyst consensus target is below the 52-week high of $137.49, yet analysts overall still recommend buying shares. The forward P/E is 17.
_________________________________
What's Your Number...?Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
For investors weighing durable payers (our Dividend Kings research covers this cohort in depth), the disconnect between fundamentals and price action is notable.
Reframing the Legacy Drag Nutrition fell 6.0% to $2.02 billion, the piece of “old Abbott” the market fixates on. Ford has been clear that this is deliberate: “We did not reduce price uniformly; we kept it focused on products that… would demonstrate a positive volume response to reduced price.”
Nutrition volume recovery, FX, $0.20 per share of Exact Sciences dilution, China volume-based procurement, and continuous glucose monitoring competition from DexCom (NASDAQ:DXCM) are genuine. Polymarket traders currently place the probability of Q2 comparable sales growth falling within the 4% to 8% band at 44% to 45%. These are the concerns of a growth-plus-quality compounder.
This article is research commentary, not investment advice.
If You’ve Been Thinking About Retirement, Pay Attention (sponsor) Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance, and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor. Here’s how:
Answer a Few Simple Questions.
Get Matched with Vetted Advisors
Choose Your Fit
Why wait? Start building the retirement you’ve always dreamed of. Get started today! (sponsor)
The healthcare company said its profit fell to $928 million, or 53 cents a share, in the second quarter, from $1.78 billion, or $1.01 a share, a year earlier.
Abbott (ABT - Free Report) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.26 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +2.34%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $1.14 per share when it actually produced earnings of $1.15, delivering a surprise of +0.88%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $12.59 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.91%. This compares to year-ago revenues of $11.14 billion. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Abbott shares have lost about 28.8% since the beginning of the year versus the S&P 500's gain of 10.6%.
What's Next for Abbott?While Abbott has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Abbott was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.42 on $13.15 billion in revenues for the coming quarter and $5.48 on $50.42 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Perrigo (PRGO - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026.
This drug company is expected to post quarterly earnings of $0.39 per share in its upcoming report, which represents a year-over-year change of -31.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Perrigo's revenues are expected to be $1 billion, down 5% from the year-ago quarter.
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8 billion, with the deal adding the clinical-stage biotechnology company's pipeline of investigational therapies for treatment-resistant depression and other mental health conditions to Lilly's neuroscience portfolio.
Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of about $2.8 billion.
Shareholders will also receive contingent value rights (CVRs) worth up to an additional $2.50 per share if specified clinical, regulatory and commercialization milestones for AtaiBeckley's lead programs are achieved, bringing the potential total equity value to about $3.8 billion.
The purchase price represents a premium of about 40% to AtaiBeckley's 30-day volume-weighted average share price through July 15, 2026, according to Lilly.
Lilly said the acquisition would strengthen its neuroscience portfolio by adding therapies designed to restore synaptic connectivity, an approach that differs from conventional antidepressants that primarily target neurotransmitter levels.
AtaiBeckley's lead candidate, BPL-003, is an intranasal synthetic form of 5-MeO-DMT being developed for treatment-resistant depression. The company said the therapy demonstrated rapid and durable reductions in depressive symptoms in a Phase 2b trial and has received Breakthrough Therapy Designation from the US Food and Drug Administration. Phase 3 activities have begun.
The company's second most advanced program, VLS-01, is a buccal film formulation of DMT that is currently being evaluated in a Phase 2b study.
"Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," Carole Ho, executive vice president and president of Lilly Neuroscience, said in a statement.
"Advancing AtaiBeckley's investigational therapies gives us a real chance to change that."
AtaiBeckley chief executive officer and co-founder Srinivas Rao said the transaction could accelerate development of the company's pipeline.
"Across our portfolio, we're seeking to demonstrate that psychiatric illness is treatable at its biological root, not just its symptoms," Rao said. "Lilly's expertise and reach are expected to accelerate that work for people whose conditions have not responded to existing treatments."
Christian Angermayer, founder, largest shareholder and chairman of AtaiBeckley, said the deal represented "the best path forward for patients and shareholders."
The transaction is expected to close in the third quarter of 2026, subject to approval by AtaiBeckley shareholders, regulatory approvals and other customary closing conditions.
Apeiron Investment Group and all AtaiBeckley directors and officers have entered voting and support agreements backing the transaction. The shares covered by those agreements represent approximately 15% of the company's outstanding common stock.
Goldman Sachs is serving as Lilly's exclusive financial adviser, while Moelis & Company and Centerview Partners are advising AtaiBeckley.
Shares of AtaiBeckley were set to open 34% higher at $7.19.
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8 billion, with the deal adding the clinical-stage biotechnology company's pipeline of investigational therapies for treatment-resistant depression and other mental health conditions to Lilly's neuroscience portfolio.
Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of about $2.8 billion.
Shareholders will also receive contingent value rights (CVRs) worth up to an additional $2.50 per share if specified clinical, regulatory and commercialization milestones for AtaiBeckley's lead programs are achieved, bringing the potential total equity value to about $3.8 billion.
The purchase price represents a premium of about 40% to AtaiBeckley's 30-day volume-weighted average share price through July 15, 2026, according to Lilly.
Lilly said the acquisition would strengthen its neuroscience portfolio by adding therapies designed to restore synaptic connectivity, an approach that differs from conventional antidepressants that primarily target neurotransmitter levels.
AtaiBeckley's lead candidate, BPL-003, is an intranasal synthetic form of 5-MeO-DMT being developed for treatment-resistant depression. The company said the therapy demonstrated rapid and durable reductions in depressive symptoms in a Phase 2b trial and has received Breakthrough Therapy Designation from the US Food and Drug Administration. Phase 3 activities have begun.
The company's second most advanced program, VLS-01, is a buccal film formulation of DMT that is currently being evaluated in a Phase 2b study.
"Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," Carole Ho, executive vice president and president of Lilly Neuroscience, said in a statement.
"Advancing AtaiBeckley's investigational therapies gives us a real chance to change that."
AtaiBeckley chief executive officer and co-founder Srinivas Rao said the transaction could accelerate development of the company's pipeline.
"Across our portfolio, we're seeking to demonstrate that psychiatric illness is treatable at its biological root, not just its symptoms," Rao said. "Lilly's expertise and reach are expected to accelerate that work for people whose conditions have not responded to existing treatments."
Christian Angermayer, founder, largest shareholder and chairman of AtaiBeckley, said the deal represented "the best path forward for patients and shareholders."
The transaction is expected to close in the third quarter of 2026, subject to approval by AtaiBeckley shareholders, regulatory approvals and other customary closing conditions.
Apeiron Investment Group and all AtaiBeckley directors and officers have entered voting and support agreements backing the transaction. The shares covered by those agreements represent approximately 15% of the company's outstanding common stock.
Goldman Sachs is serving as Lilly's exclusive financial adviser, while Moelis & Company and Centerview Partners are advising AtaiBeckley.
Shares of AtaiBeckley were set to open 34% higher at $7.19.
Medicare spent years refusing to pay for GLP-1 drugs prescribed only for weight loss. A new program called the GLP-1 Bridge changes that, although only partway and only for a limited time.
What The Bridge Actually OffersThe Eligibility Line That Decides Your PriceYou are not eligible for the Bridge if you already receive a GLP-1 through your regular Part D plan, and you are not eligible if you have type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease. That sounds backward until you see the logic. Those conditions already open a different and often stronger door, because Medicare Part D has covered GLP-1s for years when they treat a recognized medical condition rather than weight alone.
The result is a two-track system. On the first track, a qualifying diagnosis such as type 2 diabetes gets a drug like Ozempic covered through a normal Part D plan as diabetes treatment. On the second track, the Bridge catches people who lack one of those diagnoses and simply need help with weight. This also explains why Ozempic never appears on the Bridge list, since it is a diabetes drug that flows through the first track.
The Copay Catch Worth Reading TwiceA $50 copay sounds simple, and the fine print is where it stops being simple. That $50 does not count toward your deductible, and it does not count toward your annual out-of-pocket maximum. The money you spend on a Bridge medication sits outside the rest of your drug spending math, so it does not help you reach the cap that would otherwise start protecting you on everything else.
For most people that detail is a footnote, because $50 a month still crushes a $400 cash bill. For someone with a long list of prescriptions who was counting on every dollar to push them toward their out-of-pocket ceiling, the exclusion matters.
What It Means For Your MoneyThe math is direct. Paying cash at $350 a month costs $4,200 a year, while the Bridge at $50 a month costs $600, a swing of roughly $3,600 back into your budget for as long as the demonstration runs and you remain eligible.
If you qualify for the standard Part D route instead, your cost depends on your plan, and you also gain the 2026 change that caps total out-of-pocket drug spending at $2,100 for the year. Understanding which track fits you is worth real money before you assume the worst or, just as costly, assume Medicare still refuses to help at all.
The Investor Angle Behind The RolloutMedicare moved from a flat refusal to a narrow yes, priced at $50, available to a specific group, and scheduled to close at the end of 2027. For the right person, the Bridge is a strong deal that should not be left on the table, and the smart move is to confirm which of the two coverage tracks applies before building a budget around a temporary price.
For investors, the same demonstration that helps patients also feeds demand for Novo Nordisk and Eli Lilly while introducing pricing and duration risk that belongs in any thesis. None of this is investment advice, and anyone weighing these stocks or their own coverage should confirm the current details with CMS, their Part D plan, and their own research before acting.
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.
Market News and Data brought to you by Benzinga APIs
Acquisition adds category-defining SPRINT® PNS technology to Medtronic's pain therapy portfolio—the broadest in the industry.¹
, /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has completed its acquisition of SPR Therapeutics, Inc. (SPR), a privately held medical technology company and recognized leader in short-term, percutaneous peripheral nerve stimulation (PNS) therapies for chronic and acute pain management. The acquisition is valued at $650 million, consisting of an upfront cash payment.
Chronic pain affects nearly 50 million U.S. adults2, and for some, it can significantly impact their mobility, sleep quality, work performance, and overall quality of life. PNS is a form of neuromodulation that delivers mild electrical stimulation near targeted peripheral nerves to help reduce pain. As a non-opioid and non-surgical therapy, PNS can expand pain management treatment options, support earlier intervention in the care continuum, and help create additional opportunities for individualized patient care.
SPR's FDA-cleared SPRINT® PNS System is a short-term therapy designed to provide pain relief using a 60-day, minimally invasive treatment approach that does not require a permanent implant. SPRINT® is supported by a growing body of clinical research, including multiple prospective clinical studies, case series, and multi-center randomized controlled trials. Pooled results from 13 studies show that 60% of patients achieved meaningful pain relief (≥50% reduction in pain intensity) at the end of the 60-day treatment completion, with responders experiencing an average 76% reduction in pain intensity. Across all patients, there was a 56% reduction in pain intensity.3
"Medtronic is committed to expanding access to innovative therapies that can meaningfully improve patient lives," said Domenico De Paolis, Interim President of the Neuromodulation Operating Unit, part of the Medtronic Neuroscience Portfolio. "The addition of SPRINT® extends our ability to serve patients across the continuum of pain care and broadens patient access to a minimally invasive treatment option to address both chronic and acute pain."
"At SPR, our mission has always been to help people living with pain reclaim their lives," said Maria Bennett, President, Founder, and Chief Executive Officer of SPR. "We are proud of the impact our team has made in advancing innovative therapies that offer meaningful pain relief. Joining Medtronic enables us to build on that foundation, expand access to our technology, and serve more patients living with pain."
This acquisition reflects Medtronic's continued focus on strategic deals that strengthen its leadership across core businesses. It is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and neutral to accretive thereafter. The company remains committed to pursuing high-growth opportunities that complement its portfolio and enhance therapy options for physicians and hospital partners.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission – to alleviate pain, restore health, and extend life – unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit medtronic.com and follow us on LinkedIn.
About SPR
SPR is a medical technology company focused on advancing minimally invasive therapies for the treatment of pain. Its SPRINT® PNS System is designed to deliver short-term peripheral nerve stimulation therapy for sustained pain relief of up to three months following treatment and is supported by a growing body of clinical evidence and expanding reimbursement coverage. For more information on SPR Therapeutics, visit sprpainrelief.com and follow SPR on LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Medtronic Contacts:
Justin Paquette
Ingrid Goldberg
Public Relations
Investor Relations
+1-612-271-7935
[email protected]
References
Medtronic SCS Value Summary FY25; Lo Bianco, G., et al. (2025). Barriers to neuromodulation. J Anesth Analg Crit Care, 5(1):3. Lucas JW, Sohi I. Chronic pain and high-impact chronic pain in U.S. adults, 2023. NCHS Data Brief, no 518. Hyattsville, MD: National Center for Health Statistics. 2024. DOI: https://dx.doi.org/10.15620/cdc/169630. SPR SPRINT® PNS System Indications for Use. SPR Pain Relief. Accessed July 2, 2026. https://www.sprpainrelief.com/indications SOURCE Medtronic plc
ServiceNow, Inc. remains a top AI-native software pick, delivering robust Q1 2026 results and raising its full-year outlook. NOW's pivot to AI is driving tangible growth: a 22% YoY revenue increase, 23.5% RPO growth, and strong demand for AI products like Now Assist. Valuation is no longer extreme but remains at a premium; a PEG ratio of 1x reflects a 25% EPS CAGR, justifying selective accumulation.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Intuit To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Intuit between August 22, 2025 and May 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - July 16, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Intuit Inc. ("Intuit" or the "Company") (NASDAQ: INTU) and reminds investors of the September 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) they had overstated Intuit's competitive advantages and growth, as well as the overall strength and sustainability of its business model and operations; (2) in reality, Intuit was losing significant business in its tax-related business, particularly in its Turbo Tax business, as a result of, inter alia, increasing competitive and pricing pressures; (3) accordingly, Intuit's previously issued FY 2026 TurboTax revenue growth guidance was unreliable and/or unrealistic; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times.
On May 20, 2026, Intuit released its fiscal Q3 2026 financial results, which included its 2026 tax season revenue. Intuit stated that it "did not have the overall tax season we expected" and that it "faced pressure among the most price-sensitive DIY filers." Intuit said that "[w]e [lost] on price," and revealed that the Company needed to evolve its business model by delivering the right lineup and price points to meet simple filers' needs at the low end. Intuit also announced that TurboTax online paying units were expected to grow by only 2% as total IRS filers were expected to decline by approximately 30 basis points, representing the "most significant industry-wide contraction since the post-COVID tax season."
On this news, Intuit's stock price fell $76.86 per share, or 20.02%, to close at $307.07 per share on May 21, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Intuit's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Intuit class action, go to www.faruqilaw.com/INTU or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Intuit Securities Class Action Lawsuit:
What is the Intuit securities fraud lawsuit about?
The lawsuit alleges Intuit misled investors by overstating TurboTax growth, competitive strength, and FY2026 guidance while failing to disclose increasing pricing and competitive pressures.
Who may be eligible to participate in the lawsuit?
Investors who purchased Intuit (NASDAQ: INTU) securities between August 22, 2025 and May 20, 2026 may be eligible if they suffered losses.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff represents the proposed class. Eligible investors must file a motion with the court by September 8, 2026. Participation does not require serving as lead plaintiff.
What should investors do if they purchased Intuit stock during the Class Period?
Investors should review their transactions and consider consulting counsel regarding their legal rights, participation in the lawsuit, or seeking lead plaintiff status.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi has represented investors since 1995 and recovered hundreds of millions of dollars. The firm offers free evaluations of potential securities fraud claims.
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Intuit securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305337
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
, /PRNewswire/ -- As part of a historic investment to rebuild the Arsenal of Freedom, the Department of War named Lockheed Martin (NYSE: LMT) the prime contractor of U.S. Special Operations Command's (USSOCOM) next-generation logistics and sustainment support program.
SOF GLSS 2 provides a wide range of mission-critical services, including aircraft and vehicle maintenance, IT and electronics support to the U.S. Special Operations community. The $10.5 billion, 12-year contract funds the Special Operations Forces Global Logistics Support Services II (GLSS2), a competitive follow-on contract to previous ones managed by Lockheed Martin since 2010 to ensure U.S. Special Operations has the sustainment and life-cycle management to support rapid deployment and mission overmatch.
THE BIG PICTURE
Under the new contract, Lockheed Martin will continue to execute day-to-day activities and conduct sustainment and life-cycle management of:
Global supply chain of parts, warehouses and depots; Aircraft, vehicle and equipment repair, maintenance and modifications; and Critical infrastructure support and business process transformation. EXPERT PERSPECTIVE
"Lockheed Martin is deeply honored to stand beside the men and women of our Special Operations Forces," said Vic Torla, vice president, Lockheed Martin SOF GLSS. "For more than 16 years, our teams have relentlessly delivered the logistics and sustainment expertise required to accomplish our nation's most critical missions. We recognize the urgency of every operation, and our dedicated personnel, parts, and services are positioned to meet the SOF warfighter's needs. Building on the proven success with the SOF CLSS and SOF GLSS programs, we are poised to further transform SOF logistics worldwide, ensuring our exceptional operators always have what they need, when they need it." WHY IT MATTERS
SOF GLSS 2 is USSOCOM's largest service contract vehicle, providing a wide range of mission-critical services, including aircraft and vehicle maintenance, IT and electronics support to the U.S. Special Operations community.
ADDITIONAL CONTEXT
The Lockheed Martin-led Global Logistics Support Services team includes numerous subcontractor partners that provide capabilities to benefit special operations forces and ensure they receive the highest possible level of support. Lockheed Martin SOF GLSS is located at Bluegrass Station in Lexington, Kentucky, and employs over 3,300 employees worldwide. The company continues to expand its sustainment and logistics services to military and government agencies worldwide, and has a global network of people, facilities, suppliers and partners supporting around-the-clock operations. About Lockheed Martin
Lockheed Martin is a global defense technology company driving innovation and advancing scientific discovery. Our all-domain mission solutions and 21st Century Security® vision accelerate the delivery of transformative technologies to ensure those we serve always stay ahead of ready. More information at Lockheedmartin.com.
New handheld robotic technology expands the Mako platform and brings Mako robotic-assisted knee replacement to a new segment of the orthopaedic market
Stryker announced the U.S. commercial launch of Mako RPS (Robotic Power System) for total knee replacement procedures. The launch introduces Mako Handheld Robotics, expanding the Mako portfolio beyond robotic-arm assisted surgery. Mako RPS combines robotic execution, intraoperative planning and a familiar handheld power tool workflow. , /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today the U.S. commercial launch of Mako RPS® (Robotic Power System) for total knee replacement procedures, further expanding the Mako portfolio into a new category of orthopaedic robotics.
Mako RPS® (Robotic Power System)
Mako RPS® (Robotic Power System) The launch marks the introduction of the Mako Handheld Robotics platform, alongside the Mako SmartRobotics™ with Mako 4, Stryker's multi-specialty robotic-arm assisted platform. Designed to provide surgeons with an intuitive handheld robotic experience, Mako RPS combines Stryker's expertise in robotics and power tools to bring robotic technology to a new customer segment of the orthopaedic market.
"Customer response during the limited market release has been exceptionally strong," said Keith Evans, VP/GM of Stryker's Mako and Enabling Technologies business. "As we expand the Mako portfolio, we're proud to set a new standard for what customers can expect from a handheld robotics technology – bringing together robotics, power tool expertise and a deep understanding of surgical workflows."
As healthcare providers increasingly seek flexibility in how robotic technology is incorporated into orthopaedic procedures, Mako RPS offers a new option that blends robotic execution with a familiar surgical experience. The launch expands access to Mako, offering surgeons more robotic options and bringing Mako to a broader range of customers and care settings.
Compatible with Stryker's clinically proven1-2 Triathlon® Total Knee System, Mako RPS for Total Knee features intraoperative planning and a robotically enabled saw equipped with Stryker's patented active adjustment technology, which responds to a surgeon's hand movements and helps maintain alignment with the surgical plan in real time. The system provides a familiar cutting experience without the need for cutting blocks, offering an option for surgeons interested in adopting robotic technology while integrating easily into their existing surgical workflows.
"By combining robotic technology with the clinically proven Triathlon® Total Knee System, Mako RPS delivers an intuitive surgical experience that builds on the implant and workflow familiarity surgeons know and trust2-3," said Lisa Kloes, vice president and general manager of Stryker's Knee business.
Built to work with Stryker's multi-specialty Q Guidance System, Mako RPS expands Stryker's ecosystem of enabling technologies across the continuum of orthopaedic care and sites of service.
For more than two decades, Mako has defined orthopaedic robotics worldwide. With more than 2.5 million procedures performed in 47 countries, Mako continues to advance the adoption of robotics in orthopaedics and support surgeons in delivering personalized patient care.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
American Joint Replacement Registry (AJRR): 2025 Annual Report. Rosemont, IL: American Academy of Orthopaedic Surgeons (AAOS), 2025. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty Annual Report 2025. AOA;2025. https://aoanjrr.sahmri.com/. Accessed 11 Oct. 2025 Scott CEH, Snowden GT, Cawley W, et al. Fifteen-year prospective longitudinal cohort study of outcomes following single radius total knee arthroplasty. Bone Jt Open. 2023;4(10):808-816. Published 2023 Oct 24.doi:10.1302/2633-1462.410.BJO-2023-0086.R1 SOURCE Stryker
July 16, 2026 07:30 ET | Source: Cronos Group Inc.
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 second quarter earnings conference call on Thursday, August 6, 2026 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.
To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on the Company’s website.
About Cronos
Cronos is a global cannabis company focused on scaling leading consumer goods products through R&D and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS®, LIT™ and Lord Jones®. For more information about Cronos and its brands, please visit: https://thecronosgroup.com/.
Forward-looking Statements
This press release may contain information that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, “Forward-looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe” or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about Cronos’ intention to build an iconic brand portfolio and its focus on scaling leading consumer goods products through R&D and innovation. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, each of which have been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.
